library_books Research Sources & References
Research papers, clinical guidance and further reading, grouped by topic. Follow numbered references on each guide to find the sources used for that text.
How to use this page
The library contains 205 distinct papers across 13 topics, with at least 20 selected papers per topic. Citation metadata was checked on 10 September 2026. Some papers support the guides; others are selected for further assessment.
If you are newly diagnosed, you do not need to read everything here. Start with the sections that match the question you are trying to answer right now.
Read the study type, population and limitations together. Expert consensus may guide care despite limited trials; a small study or laboratory result does not establish treatment benefit. Assessment labels describe how much of a paper was examined, not clinical approval of the website.
m.3243A>G foundations
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. (2008). Pathogenic mitochondrial DNA mutations are common in the general population. American journal of human genetics. open_in_new
Findings: Screening of neonatal cord blood found pathogenic mtDNA variants in people without selected clinical disease; carrier prevalence is distinct from symptomatic disease prevalence.
Population: 3168 neonatal cord-blood samples screened for ten variants
Limits: One population and assay strategy; the combined mtDNA rate is not an m.3243A>G disease rate.
Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. open_in_new
Findings: Age and tissue affect heteroplasmy measurements. Relationships with disease burden are useful at cohort level but do not precisely predict one person’s course.
Population: m.3243A>G cohort; blood 231, urine 235, muscle 77
Limits: Observational tissue comparisons; cohorts overlap other UK reports.
Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Kärppä M, Majamaa-Voltti KA, Rusanen H, Sorri M, Peuhkurinen KJ, Hassinen IE. (1998). Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. American journal of human genetics. open_in_new
Findings: Study identified 11 pedigrees and estimated a minimum regional adult variant prevalence.
Population: Adult population of 245201 with symptom/family-based ascertainment
Limits: Clinical ascertainment underdetects asymptomatic carriers; historic regional minimum is not a worldwide prevalence or MELAS risk.
Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, Sue CM. (2007). Population prevalence of the MELAS A3243G mutation. Mitochondrion. open_in_new
Findings: Population screening detected m.3243A>G more often than clinical diagnosis counts would suggest.
Population: 2,954 predominantly White older adults; seven mutation-positive participants
Limits: Age, ancestry and assay-specific prevalence; carrier prevalence differs from symptomatic disease prevalence.
Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: A UK cohort showed MELAS, MIDD, overlap, PEO, isolated manifestations and clinically asymptomatic carriers.
Population: 129 people from 83 families in a UK mitochondrial cohort
Limits: Clinical and family ascertainment; percentages are not population prevalence or future risk.
Murphy R, Turnbull DM, Walker M, Hattersley AT. (2008). Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabetic medicine : a journal of the British Diabetic Association. open_in_new
Findings: Summarises phenotype, diagnostic clues, prevalence literature and management considerations.
Population: MIDD clinical review
Limits: Historical review; current medication and genetic guidance can differ.
Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. (1997). Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain : a journal of neurology. open_in_new
Findings: Clinical feature frequency correlated with muscle mutation load in this cohort; blood mutation load did not show the same relationship.
Population: 245 carriers of m.3243A>G or m.8344A>G
Limits: Mixed variants and selected tissues; association is not a deterministic prognosis or universal threshold.
Picard M, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, O'Hearn S, Levy S, Potluri P, Lvova M, Davila A, Lin CS, Perin JC, Rappaport EF, Hakonarson H, Trounce IA, Procaccio V, Wallace DC. (2014). Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. Proceedings of the National Academy of Sciences of the United States of America. open_in_new
Findings: Increasing mutant fractions produced changes in transcription, morphology and oxidative capacity.
Population: m.3243A>G transmitochondrial cybrid cell lines
Limits: Cell-model thresholds and broad introductory phenotype claims are not validated patient heteroplasmy cut-offs.
Yarham JW, Elson JL, Blakely EL, McFarland R, Taylor RW. (2010). Mitochondrial tRNA mutations and disease. Wiley interdisciplinary reviews. RNA. open_in_new
Findings: Reviews mechanisms, variable phenotype, inheritance and experimental models.
Population: Review of mitochondrial tRNA mutations
Limits: Mechanistic synthesis; model findings cannot be treated as clinical therapy.
Kopinski PK, Janssen KA, Schaefer PM, Trefely S, Perry CE, Potluri P, Tintos-Hernandez JA, Singh LN, Karch KR, Campbell SL, Doan MT, Jiang H, Nissim I, Nakamaru-Ogiso E, Wellen KE, Snyder NW, Garcia BA, Wallace DC. (2019). Regulation of nuclear epigenome by mitochondrial DNA heteroplasmy. Proceedings of the National Academy of Sciences of the United States of America. open_in_new
Findings: Heteroplasmy-dependent metabolic changes were linked to nuclear histone modifications and gene expression.
Population: m.3243A>G cybrid cell models
Limits: Cellular mechanisms do not establish patient syndrome thresholds or a treatment.
Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. (2011). Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. open_in_new
Findings: MELAS can cause significant progressive neurological burden, but the observed disease course differs among people.
Population: m.3243A>G-associated MELAS natural-history cohort
Limits: Selected clinical cohort; cannot predict an individual’s survival or future function.
Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. open_in_new
Findings: Clinical manifestations vary greatly among m.3243A>G carriers; age and measured heteroplasmy provide limited individual phenotype prediction.
Population: 238 adults with m.3243A>G
Limits: Selected adult cohort; associations do not determine an individual prognosis.
de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. (2012). Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. Journal of inherited metabolic disease. open_in_new
Findings: Reports variable features and tissue/age-dependent heteroplasmy, supporting urinary epithelial testing.
Population: 34 Dutch families, 82 carriers among 127 participants
Limits: Related family members and selected cohort; contains a correction and cannot define individual severity.
Rajasimha HK, Chinnery PF, Samuels DC. (2008). Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood. American journal of human genetics. open_in_new
Findings: Models selection against m.3243A>G in blood stem-cell lineages and age-related decline in blood heteroplasmy.
Population: Human heteroplasmy data and haematopoietic simulations
Limits: Model-dependent correction; blood heteroplasmy is not whole-body load.
Uusimaa J, Moilanen JS, Vainionpää L, Tapanainen P, Lindholm P, Nuutinen M, Löppönen T, Mäki-Torkko E, Rantala H, Majamaa K. (2007). Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Annals of neurology. open_in_new
Findings: A population study found variable childhood features and transmission patterns, including learning and exercise difficulties.
Population: Defined Finnish paediatric population; 18 identified children plus family analyses
Limits: Geographically specific ascertainment and small family sample; transmission rates are not individual predictions.
Whittaker RG, Blackwood JK, Alston CL, Blakely EL, Elson JL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. (2009). Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. Neurology. open_in_new
Findings: Bibliographic record verified; no abstract available in the retrieved record. Full text must be assessed before using this source to support a claim.
Population: Not yet extracted
Limits: No findings assessed. Title alone is not evidence.
Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. (1998). MELAS and MERRF. The relationship between maternal mutation load and the frequency of clinically affected offspring. Brain : a journal of neurology. open_in_new
Findings: Higher maternal blood mutation load was associated with more affected offspring; authors explicitly warned against using results for absolute pregnancy risks.
Population: Pedigrees with m.3243A>G or m.8344A>G
Limits: Retrospective selected pedigrees and tissue-specific heteroplasmy; requires specialist counselling, not individual risk percentages.
Boggan RM, Michalettou TD, Ng YS, Franklin IG, Cortés LT, Alston CL, Blakely EL, Büchner B, Bugiardini E, Colclough K, Feeney C, Hanna MG, Hattersley AT, Klopstock T, Kornblum C, Mancuso M, Patel KA, Pitceathly RDS, Pizzamiglio C, Prokisch H, Schäfer J, Schaefer AM, Shepherd MH, Thaele A, Thomas RH, Turnbull DM, Woodward CE, McFarland R, Taylor RW, Cordell HJ, Pickett SJ. (2026). Identification of Nuclear Genetic Loci Linked to Clinical Features of the m.3243A>G Mitochondrial DNA Variant. Neurology. Genetics. open_in_new
Findings: Linkage implicated chromosome 7q22 for encephalopathy; candidate variants and genes did not reach corrected association thresholds.
Population: 488 clinically ascertained m.3243A>G carriers; 198 in linkage analysis
Limits: Exploratory modifier genetics; not a validated individual prognostic test. Cohort overlap with earlier consortium work needs checking.
Chanoine JP, Thompson DM, Lehman A. (2025). Diabetes Associated With Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes. open_in_new
Findings: MIDD commonly combines mitochondrial diabetes and sensorineural hearing loss, with variable onset and multisystem involvement. Insulin secretion and insulin resistance both contribute.
Population: MIDD literature; mostly m.3243A>G
Limits: Narrative review; heterogeneous selected cohorts. Prevalence and phenotype frequencies are not individual predictions.
Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. open_in_new
Findings: m.3243A>G is an A-to-G substitution in mitochondrial tRNA-Leu(UUR); the discovery series demonstrated heteroplasmy and association with MELAS.
Population: 31 independent MELAS cases, other disease groups and controls
Limits: Foundational association study; historical phenotype labels are narrower than later evidence.
MIDD
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Maassen JA, 'T Hart LM, Van Essen E, Heine RJ, Nijpels G, Jahangir Tafrechi RS, Raap AK, Janssen GM, Lemkes HH. (2004). Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. open_in_new
Findings: The review describes impaired insulin secretion and age-related beta-cell dysfunction in m.3243A>G disease.
Population: Review of mitochondrial diabetes mechanisms
Limits: Historical mechanistic review; newer evidence recognises coexisting insulin resistance and heterogeneous treatment needs.
Murphy R, Turnbull DM, Walker M, Hattersley AT. (2008). Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabetic medicine : a journal of the British Diabetic Association. open_in_new
Findings: Summarises phenotype, diagnostic clues, prevalence literature and management considerations.
Population: MIDD clinical review
Limits: Historical review; current medication and genetic guidance can differ.
Guillausseau PJ, Massin P, Dubois-LaForgue D, Timsit J, Virally M, Gin H, Bertin E, Blickle JF, Bouhanick B, Cahen J, Caillat-Zucman S, Charpentier G, Chedin P, Derrien C, Ducluzeau PH, Grimaldi A, Guerci B, Kaloustian E, Murat A, Olivier F, Paques M, Paquis-Flucklinger V, Porokhov B, Samuel-Lajeunesse J, Vialettes B. (2001). Maternally inherited diabetes and deafness: a multicenter study. Annals of internal medicine. open_in_new
Findings: A prospective descriptive MIDD study reports variable insulin requirements and hearing, retinal, renal, muscle and cardiac involvement.
Population: 54 m.3243A>G patients with diabetes across 16 French departments
Limits: Diabetes-based recruitment; historical cohort percentages should not be applied to all carriers.
van den Ouweland JM, Lemkes HH, Trembath RC, Ross R, Velho G, Cohen D, Froguel P, Maassen JA. (1994). Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single point mutation in the mitochondrial tRNA(Leu(UUR)) gene. Diabetes. open_in_new
Findings: Early family study linked maternally inherited diabetes and deafness to m.3243A>G and proposed the MIDD designation.
Population: Dutch, French and British pedigrees with diabetes and deafness
Limits: Selected pedigrees establish phenotype association, not penetrance or population prevalence.
de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. (2012). Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. Journal of inherited metabolic disease. open_in_new
Findings: Reports variable features and tissue/age-dependent heteroplasmy, supporting urinary epithelial testing.
Population: 34 Dutch families, 82 carriers among 127 participants
Limits: Related family members and selected cohort; contains a correction and cannot define individual severity.
Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, Donati A, Minetti C, Moggio M, Mongini T, Servidei S, Tonin P, Toscano A, Uziel G, Bruno C, Ienco EC, Filosto M, Lamperti C, Catteruccia M, Moroni I, Musumeci O, Pegoraro E, Ronchi D, Santorelli FM, Sauchelli D, Scarpelli M, Sciacco M, Valentino ML, Vercelli L, Zeviani M, Siciliano G. (2014). The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? Journal of neurology. open_in_new
Findings: Confirms broad phenotype variability and reports a possible male association with stroke-like episodes.
Population: 126 Italian m.3243A>G carriers in a retrospective database
Limits: Exploratory sex association and referral selection; MIDD or PEO labels do not confer a fixed prognosis.
Karaa A, Goldstein A. (2015). The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes. Pediatric diabetes. open_in_new
Findings: Discusses clinical and pathogenic distinctions from more common diabetes forms.
Population: Review of mitochondrial forms of diabetes
Limits: Mixed genotypes and historical review; not a current treatment algorithm.
Finsterer J. (2007). Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation. Acta neurologica Scandinavica. open_in_new
Findings: The review describes syndromic and nonsyndromic multisystem presentations and possible modifiers.
Population: Review of A3243G genetics and phenotypes
Limits: Historical review; syndromic frequencies and diagnostic practice require newer evidence.
Maassen JA, Janssen GM, 't Hart LM. (2005). Molecular mechanisms of mitochondrial diabetes (MIDD). Annals of medicine. open_in_new
Findings: The review discusses reduced glucose-stimulated insulin secretion and beta-cell ageing in m.3243A>G disease.
Population: Mechanistic review of mitochondrial diabetes
Limits: Mechanistic synthesis; not comparative evidence for a medicine choice.
Katagiri H, Asano T, Ishihara H, Inukai K, Anai M, Yamanouchi T, Tsukuda K, Kikuchi M, Kitaoka H, Ohsawa N. (1994). Mitochondrial diabetes mellitus: prevalence and clinical characterization of diabetes due to mitochondrial tRNA(Leu(UUR)) gene mutation in Japanese patients. Diabetologia. open_in_new
Findings: Screening described variable onset and progressive insulin secretory impairment in selected m.3243A>G families.
Population: 300 Japanese diabetes patients with maternal diabetes; four variant-positive pedigrees
Limits: Abstract is truncated; enriched screening and small pedigrees do not yield general prevalence or universal treatment trajectories.
Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, Caillat-Zucman S, Froguel P, Paquis-Fluckinger V, Gaudric A, Guillausseau PJ. (1999). Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology. open_in_new
Findings: Macular pattern dystrophy occurred in a selected MIDD series, often with relatively preserved visual acuity.
Population: 35 people with MIDD
Limits: Selected ophthalmic series; frequency cannot be generalised to every carrier.
Velho G, Byrne MM, Clément K, Sturis J, Pueyo ME, Blanché H, Vionnet N, Fiet J, Passa P, Robert JJ, Polonsky KS, Froguel P. (1996). Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes. open_in_new
Findings: Impaired glucose-regulated insulin secretion appeared even in some carriers with normal glucose tolerance; overt diabetes also involved insulin resistance.
Population: 25 carriers from five French pedigrees; seven detailed metabolic assessments
Limits: Small selected physiological study; heterogeneous results do not predict individual progression.
Szendroedi J, Schmid AI, Meyerspeer M, Cervin C, Kacerovsky M, Smekal G, Gräser-Lang S, Groop L, Roden M. (2009). Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes care. open_in_new
Findings: Clamp and spectroscopy measurements demonstrated insulin resistance with impaired muscle ATP synthesis.
Population: One female MELAS patient and six controls
Limits: Single-patient physiology; supports possibility rather than frequency or causal certainty.
Laloi-Michelin M, Meas T, Ambonville C, Bellanné-Chantelot C, Beaufils S, Massin P, Vialettes B, Gin H, Timsit J, Bauduceau B, Bernard L, Bertin E, Blickle JF, Cahen-Varsaux J, Cailleba A, Casanova S, Cathebras P, Charpentier G, Chedin P, Crea T, Delemer B, Dubois-Laforgue D, Duchemin F, Ducluzeau PH, Bouhanick B, Dusselier L, Gabreau T, Grimaldi A, Guerci B, Jacquin V, Kaloustian E, Larger E, Lecleire-Collet A, Lorenzini F, Louis J, Mausset J, Murat A, Nadler-Fluteau S, Olivier F, Paquis-Flucklinger V, Paris-Bockel D, Raynaud I, Reznik Y, Riveline JP, Schneebeli S, Sonnet E, Sola-Gazagnes A, Thomas JL, Trabulsi B, Virally M, Guillausseau PJ, Mitochondrial Diabetes French Study Group. (2009). The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. The Journal of clinical endocrinology and metabolism. open_in_new
Findings: Blood heteroplasmy correlated with selected clinical measures; age adjustment changed some associations.
Population: 89 MIDD patients in the GEDIAM register; MELAS excluded
Limits: Register-based selected population; overlaps the GEDIAM research programme and is not a personal forecast.
Chanoine JP, Thompson DM, Lehman A. (2025). Diabetes Associated With Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes. open_in_new
Findings: MIDD commonly combines mitochondrial diabetes and sensorineural hearing loss, with variable onset and multisystem involvement. Insulin secretion and insulin resistance both contribute.
Population: MIDD literature; mostly m.3243A>G
Limits: Narrative review; heterogeneous selected cohorts. Prevalence and phenotype frequencies are not individual predictions.
Chaudhry A, Thompson DM, Chanoine JP. (2026). Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm. Diabetes, obesity & metabolism. open_in_new
Findings: Treatment is individualised to insulin reserve, glucose control, nutrition and organ disease. Authors propose several agents, including conditional metformin use; no MIDD-specific randomised treatment trials establish a preferred sequence.
Population: MIDD; recommendations partly extrapolated from type 2 diabetes
Limits: Proposed algorithm, not a validated guideline; direct MIDD drug comparisons are lacking.
Oppenheimer KR, Himelhoch NT, McCullough ME, Bowden TL, Kandasamy B, Letourneau-Freiberg LR, Naylor RN, Greeley SAW, Philipson LH. (2026). Approach to the Patient: Mitochondrial Diabetes: Contemporary Cases and a Precision Medicine Approach. The Journal of clinical endocrinology and metabolism. open_in_new
Findings: Registry cases illustrate hearing and muscle involvement, variable familial heteroplasmy and differing diabetes regimens.
Population: 15 mitochondrial diabetes probands; three detailed cases
Limits: Selected small cohort; subjective supplement improvement and medication use are not efficacy or safety evidence.
Varga L, Borecka S, Skopkova M, Rambani V, Sklenar M, Cipkova K, Kickova T, Ugorova D, Kabatova Z, Stanik J, Profant M, Gasperikova D. (2026). Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients. Ear and hearing. open_in_new
Findings: Cochlear implantation produced useful long-term hearing outcomes in three individuals in the reported m.3243A>G series.
Population: m.3243A>G cases identified during Slovak hearing-loss screening
Limits: Small selected implant series; outcome varies and requires specialist assessment.
Rindell N, Immonen H, Martikainen MH. (2026). Prevalence and treatment of mitochondrial diabetes in Southwest Finland. Journal of diabetes and metabolic disorders. open_in_new
Findings: Regional records describe variable onset, frequent hearing impairment and common progression to insulin therapy.
Population: 17 mitochondrial diabetes patients in Southwest Finland
Limits: Small regional ascertainment study; treatment timing and prevalence do not predict an individual course.
Semmler L, Büchner B, Kornblum C, Deschauer M, Wortmann S, La Morgia C, Servidei S, Freisinger P, Mensch A, Schuelke M, Prokisch H, Mancuso M, Lamperti C, Klopstock T, GENOMIT study group. (2026). Mitochondrial diabetes mellitus: real world insights from the GENOMIT registry-a multinational, longitudinal cohort study. EBioMedicine. open_in_new
Findings: Diabetes occurred in 177/360 m.3243A>G carriers in this clinical registry. Metformin use and discontinuation varied; authors call for caution and prospective genotype-informed evidence rather than universal avoidance.
Population: GENOMIT registry: 2399 patients, 360 m.3243A>G carriers
Limits: Registry selection, confounding and retrospective exposure do not establish drug safety or general population risk.
MELAS
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. open_in_new
Findings: MELAS is a clinical syndrome including stroke-like episodes associated with pathogenic mtDNA; the m.3243A>G variant alone does not establish MELAS. New stroke-like symptoms require urgent assessment and suspected seizures need prompt treatment. Efficacy of arginine, citrulline, taurine and routine supplements remains unproven.
Population: MELAS / stroke-like episodes
Limits: Consensus based on limited therapeutic evidence; no self-treatment regimen follows from these statements.
Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. open_in_new
Findings: Valproate is contraindicated in POLG disease and hepatic-risk settings; use in non-POLG disease without liver impairment requires individual specialist judgement.
Population: Primary mitochondrial diseases; POLG exception explicit
Limits: Expert consensus; absence of a contraindication does not prove universal safety.
Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, Martikainen MH, Mcfarland R, Nesbitt V, Pitceathly RDS, Schaefer AM, Turnbull DM. (2019). Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome open research. open_in_new
Findings: Frames stroke-like episodes as an epileptic encephalopathy and prioritises early seizure management.
Population: European expert consensus on stroke-like episodes
Limits: Expert consensus with acknowledged lack of randomised treatment evidence; compare 2026 update.
Stefanetti RJ, Ng YS, Errington L, Blain AP, McFarland R, Gorman GS. (2022). l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review. Neurology. open_in_new
Findings: No randomised trials were found among 37 reports involving 91 people. Study quality and concurrent treatments prevent confident attribution of benefit to IV or oral arginine.
Population: 91 people; most had m.3243A>G
Limits: Very low quality evidence, uncontrolled reports and co-interventions; efficacy remains unresolved.
El-Hattab AW, Adesina AM, Jones J, Scaglia F. (2015). MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular genetics and metabolism. open_in_new
Findings: MELAS can involve stroke-like episodes, seizures, lactic acidosis, myopathy and other organs. The proposed mechanisms are multiple and incompletely resolved.
Population: MELAS literature review
Limits: Narrative review; older management suggestions must be checked against newer consensus.
Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. open_in_new
Findings: m.3243A>G is an A-to-G substitution in mitochondrial tRNA-Leu(UUR); the discovery series demonstrated heteroplasmy and association with MELAS.
Population: 31 independent MELAS cases, other disease groups and controls
Limits: Foundational association study; historical phenotype labels are narrower than later evidence.
Kobayashi Y, Momoi MY, Tominaga K, Momoi T, Nihei K, Yanagisawa M, Kagawa Y, Ohta S. (1990). A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochemical and biophysical research communications. open_in_new
Findings: Identified the conserved MT-TL1 A-to-G substitution at nucleotide 3243 in MELAS.
Population: Six MELAS patients and 11 controls in early mutation analysis
Limits: Foundational small discovery study; does not define the complete phenotype spectrum.
Ciafaloni E, Ricci E, Shanske S, Moraes CT, Silvestri G, Hirano M, Simonetti S, Angelini C, Donati MA, Garcia C. (1992). MELAS: clinical features, biochemistry, and molecular genetics. Annals of neurology. open_in_new
Findings: Mutation levels varied between tissue and clinical groups; blood testing missed some asymptomatic relatives.
Population: 23 MELAS patients, 25 maternal relatives and 50 mitochondrial disease controls
Limits: Historical selected cohort; muscle mutation proportions do not define clinical thresholds.
Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, DiMauro S, Rowland LP. (1992). Melas: an original case and clinical criteria for diagnosis. Neuromuscular disorders : NMD. open_in_new
Findings: The paper proposed early MELAS criteria including onset before 40 and recognised incomplete and overlapping presentations.
Population: Historical index case and review of 69 reported MELAS cases
Limits: Historical criteria; later consensus supersedes rigid age-based exclusion.
Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. (1992). Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology. open_in_new
Findings: A clinical-biochemical series found variable respiratory-chain and biopsy findings, including absence of ragged-red fibres in some cases.
Population: 40 clinically defined MELAS patients, 32 with m.3243A>G
Limits: Historical selected MELAS cohort; frequencies are not general carrier risks.
Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, Kakuma T, Koga Y, Taro Matsuoka for MELAS Study Group in Japan. (2012). MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochimica et biophysica acta. open_in_new
Findings: Reports different juvenile and adult clinical courses and disease burden over follow-up.
Population: 96 Japanese MELAS patients followed prospectively
Limits: Selected clinically defined MELAS cohort; progression estimates do not apply to all m.3243A>G carriers.
Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: A UK cohort showed MELAS, MIDD, overlap, PEO, isolated manifestations and clinically asymptomatic carriers.
Population: 129 people from 83 families in a UK mitochondrial cohort
Limits: Clinical and family ascertainment; percentages are not population prevalence or future risk.
Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. (2011). Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. open_in_new
Findings: MELAS can cause significant progressive neurological burden, but the observed disease course differs among people.
Population: m.3243A>G-associated MELAS natural-history cohort
Limits: Selected clinical cohort; cannot predict an individual’s survival or future function.
Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS, Hong X, Gooch CL, Mao X, Pascual JM, Hirano M, Stacpoole PW, DiMauro S, De Vivo DC. (2006). Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. open_in_new
Findings: A randomised MELAS trial was stopped early because DCA caused onset or worsening of peripheral neuropathy, with no demonstrated clinical benefit.
Population: 30 people aged 10–60 with m.3243A>G-associated MELAS
Limits: Studied regimen and population; do not generalise to every investigational metabolic indication.
Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. (2018). Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. Journal of neurology. open_in_new
Findings: Small prospective Japanese oral and IV studies reported symptom and episode-related signals with arginine.
Population: 15 oral-treatment and 10 IV-treatment participants
Limits: No randomised comparator; small cohorts; natural variation and other treatments complicate attribution.
Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y, KN01 Study Group. (2019). Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: Ten people received high-dose taurine in a 52-week open-label trial; fewer episodes were reported, but no placebo comparison establishes causality.
Population: 10 people with MELAS and recurrent stroke-like episodes
Limits: Uncontrolled small study, wide confidence intervals; not proof of prevention or general m.3243A>G benefit.
Iizuka T, Sakai F, Suzuki N, Hata T, Tsukahara S, Fukuda M, Takiyama Y. (2002). Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology. open_in_new
Findings: Imaging, EEG and perfusion observations support neuronal hyperexcitability as one contributor to stroke-like lesions.
Population: 14 stroke-like episodes in six MELAS patients
Limits: Small episode-based series; mechanistic interpretation, not proof of a treatment effect.
Li Y, Han S, Huang D, Chen J, Qu S, Gu J, Xu Z, Fu L, Tang X, Qiao Y. (2026). Mitochondrial mutation status, symptom prevalence, and neuroimaging characteristics in MELAS: a systematic review and meta analysis. Orphanet journal of rare diseases. open_in_new
Findings: Meta-analysis described genotype, symptoms and imaging in diagnosed MELAS cohorts.
Population: 13 MELAS studies comprising 988 subjects
Limits: Large uncertainty and heterogeneity; MELAS-selected proportions must not be treated as risks in all m.3243A>G carriers. Proposed targets are not treatments.
Molla GK, Uzun ÖÜ, Agakisili HB, Genç E, Gülten ZA, Yıldırım T, Ersoy AS, Ak B, Gülbahçe A, Yıldız S, Çakar NE, Karaca M, Zübarioğlu T, Hişmi BÖ, Erdöl Ş, Önal H, Kara B, Gökçay GF. (2025). Profiles of paediatric patients experiencing stroke-like episodes associated with mitochondrial disease. Frontiers in neurology. open_in_new
Findings: Stroke-like episodes occurred across mitochondrial genotypes; MRI and EEG contributed to assessment. Authors observed improvement after acute arginine in MELAS cases.
Population: 34 children with genetic mitochondrial disease; 13 with stroke-like episodes
Limits: Retrospective, small mixed-genotype cohort; uncontrolled improvement does not establish arginine efficacy.
Tang H, Liu J, Cai X, Leng F, Hu J, Zhao Y, Wang Z, Yu L. (2026). Analysis of acute stroke-like lesions in MELAS: Distribution, potential boundaries and spreading pattern. Neuroimage. Reports. open_in_new
Findings: Acute stroke-like lesions have distributions and spreading patterns that can differ from vascular-territory infarction.
Population: Patients with MELAS acute stroke-like lesions
Limits: Imaging study; radiological patterns are not a home diagnostic test.
Symptoms and organ involvement
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: A UK cohort showed MELAS, MIDD, overlap, PEO, isolated manifestations and clinically asymptomatic carriers.
Population: 129 people from 83 families in a UK mitochondrial cohort
Limits: Clinical and family ascertainment; percentages are not population prevalence or future risk.
de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. (2012). Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. Journal of inherited metabolic disease. open_in_new
Findings: Reports variable features and tissue/age-dependent heteroplasmy, supporting urinary epithelial testing.
Population: 34 Dutch families, 82 carriers among 127 participants
Limits: Related family members and selected cohort; contains a correction and cannot define individual severity.
Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. open_in_new
Findings: Clinical manifestations vary greatly among m.3243A>G carriers; age and measured heteroplasmy provide limited individual phenotype prediction.
Population: 238 adults with m.3243A>G
Limits: Selected adult cohort; associations do not determine an individual prognosis.
Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, Donati A, Minetti C, Moggio M, Mongini T, Servidei S, Tonin P, Toscano A, Uziel G, Bruno C, Ienco EC, Filosto M, Lamperti C, Catteruccia M, Moroni I, Musumeci O, Pegoraro E, Ronchi D, Santorelli FM, Sauchelli D, Scarpelli M, Sciacco M, Valentino ML, Vercelli L, Zeviani M, Siciliano G. (2014). The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? Journal of neurology. open_in_new
Findings: Confirms broad phenotype variability and reports a possible male association with stroke-like episodes.
Population: 126 Italian m.3243A>G carriers in a retrospective database
Limits: Exploratory sex association and referral selection; MIDD or PEO labels do not confer a fixed prognosis.
Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. (2001). Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney international. open_in_new
Findings: A renal series links podocyte mitochondrial abnormalities and FSGS with m.3243A>G; some patients later developed diabetes or hearing symptoms.
Population: Seven selected FSGS patients tested; four m.3243A>G-positive women
Limits: Selected small retrospective series; observed renal decline is not a population prognosis.
Guéry B, Choukroun G, Noël LH, Clavel P, Rötig A, Lebon S, Rustin P, Bellané-Chantelot C, Mougenot B, Grünfeld JP, Chauveau D. (2003). The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. Journal of the American Society of Nephrology : JASN. open_in_new
Findings: Kidney manifestations associated with m.3243A>G include glomerular and tubular disease.
Population: Nine patients with renal presentations
Limits: Selected renal case series; cannot estimate prevalence.
Wahbi K, Bougouin W, Béhin A, Stojkovic T, Bécane HM, Jardel C, Berber N, Mochel F, Lombès A, Eymard B, Duboc D, Laforêt P. (2015). Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. European heart journal. open_in_new
Findings: Long-term retrospective cardiac study identified baseline features associated with major cardiac events.
Population: 260 adults with mixed mitochondrial genotypes, including 64 m.3243A>G
Limits: Heterogeneous referral cohort and composite endpoint; rates are not general carrier risks.
Majamaa-Voltti K, Peuhkurinen K, Kortelainen ML, Hassinen IE, Majamaa K. (2002). Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G. BMC cardiovascular disorders. open_in_new
Findings: Cardiac assessment identified structural, functional and rhythm abnormalities; left ventricular hypertrophy correlated with clinical burden.
Population: 39 m.3243A>G patients, comparison group and 17 autopsy reports
Limits: Small selected cohort and wide confidence intervals; does not establish a universal 56% risk.
Chinnery PF, Elliott C, Green GR, Rees A, Coulthard A, Turnbull DM, Griffiths TD. (2000). The spectrum of hearing loss due to mitochondrial DNA defects. Brain : a journal of neurology. open_in_new
Findings: Clinical testing suggests that cochlear dysfunction contributes importantly to hearing loss in mitochondrial disease.
Population: 23 patients with different mitochondrial DNA disorders
Limits: Mixed genotypes; findings do not guarantee preservation of auditory nerve function.
Sue CM, Lipsett LJ, Crimmins DS, Tsang CS, Boyages SC, Presgrave CM, Gibson WP, Byrne E, Morris JG. (1998). Cochlear origin of hearing loss in MELAS syndrome. Annals of neurology. open_in_new
Findings: Hearing loss is often bilateral, progressive and high-frequency predominant, with variation in onset and severity.
Population: 18 patients from four m.3243A>G kindreds
Limits: Small selected sample; not every patient follows this pattern.
Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, Caillat-Zucman S, Froguel P, Paquis-Fluckinger V, Gaudric A, Guillausseau PJ. (1999). Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology. open_in_new
Findings: Macular pattern dystrophy occurred in a selected MIDD series, often with relatively preserved visual acuity.
Population: 35 people with MIDD
Limits: Selected ophthalmic series; frequency cannot be generalised to every carrier.
Uehara N, Fujita T, Uehara K, Shimoda H, Yamashita D, Yokoi J, Katsunuma S, Kakigi A, Nibu KI. (2026). Clinical characteristics and hearing impairment in carriers of the m.3243 A > G variant. Journal of human genetics. open_in_new
Findings: Hearing loss was often post-lingual sensorineural loss; more severe loss was associated with multisystem disease. Two patients with initial MIDD features developed MELAS.
Population: 37 retrospectively assessed m.3243A>G carriers
Limits: Selected retrospective cohort; does not establish a universal progression path or rate.
Jouda H, Browning AC, Aftab AM, Mahmoud I, Bibi S, McFarland R, Pickett SJ, Devine H. (2025). Macular OCT inner retinal changes reflect CNS involvement in m.3243A>G disease. BMJ neurology open. open_in_new
Findings: Temporal retinal nerve fibre layer thinning was associated with neurological involvement, suggesting a potential biomarker.
Population: 29 m.3243A>G carriers undergoing OCT
Limits: Small cross-sectional sample; predictive value and longitudinal progression unproven.
Nielsen SR, Stoico MP, Liao D, Drewes AM, Pedersen IS, Frederiksen AL, Brock C. (2025). Prolonged Gastrointestinal Transit Times and Dysmotility in m.3243A>G Mitochondrial Disease. Neurogastroenterology and motility. open_in_new
Findings: Measured gastric and colonic transit abnormalities did not correlate with perceived GI symptom scores.
Population: 22 Danish m.3243A>G carriers and 22 matched controls
Limits: Small selected cohort; physiological measures alone do not dictate an individual diet or symptom explanation.
de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. (2015). Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. The Netherlands journal of medicine. open_in_new
Findings: Swallowing and gastrointestinal problems, including constipation, can contribute to malnutrition in m.3243A>G disease.
Population: 92 m.3243A>G carriers
Limits: Observational cohort; symptom burden varies; no tested dietary prescription.
Winqvist S, Kärppä M, Moilanen JS, Majamaa K. (2025). Cognitive impairment profile in patients with the m.3243A> G variant in mitochondrial DNA. BMC neurology. open_in_new
Findings: Neuropsychological assessment found variable impairment across domains, associated with phenotype burden and heteroplasmy.
Population: 45 adult m.3243A>G patients and 45 healthy controls
Limits: Selected observational cohort; does not establish inevitable major impairment or future decline.
Verhaak C, de Laat P, Koene S, Tibosch M, Rodenburg R, de Groot I, Knoop H, Janssen M, Smeitink J. (2016). Quality of life, fatigue and mental health in patients with the m.3243A > G mutation and its correlates with genetic characteristics and disease manifestation. Orphanet journal of rare diseases. open_in_new
Findings: Fatigue and mental health symptoms can affect quality of life in m.3243A>G disease; mutation load alone is not an adequate explanation.
Population: 72 adult m.3243A>G carriers
Limits: Questionnaire measures are not equivalent to a clinical psychiatric diagnosis; cross-sectional associations.
Uusimaa J, Moilanen JS, Vainionpää L, Tapanainen P, Lindholm P, Nuutinen M, Löppönen T, Mäki-Torkko E, Rantala H, Majamaa K. (2007). Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Annals of neurology. open_in_new
Findings: A population study found variable childhood features and transmission patterns, including learning and exercise difficulties.
Population: Defined Finnish paediatric population; 18 identified children plus family analyses
Limits: Geographically specific ascertainment and small family sample; transmission rates are not individual predictions.
Shen X, Du A. (2021). The non-syndromic clinical spectrums of mtDNA 3243A>G mutation. Neurosciences (Riyadh, Saudi Arabia). open_in_new
Findings: Describes multisystem features that do not fit a single named syndrome.
Population: Review of nonsyndromic m.3243A>G manifestations
Limits: Heterogeneous literature and phenotype definitions; frequencies are not individual predictions.
Cox BC, Pearson JY, Mandrekar J, Gavrilova RH. (2023). The clinical spectrum of MELAS and associated disorders across ages: a retrospective cohort study. Frontiers in neurology. open_in_new
Findings: Retrospective study shows variable presentation and later-onset stroke-like episodes, including after age 40.
Population: 81 patients/carriers: 42 MELAS, 30 symptomatic non-MELAS, nine asymptomatic
Limits: Selected cohort and exploratory comparisons; individual prognosis cannot be inferred from group mortality estimates.
Diagnosis and monitoring
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, Knowles CVY, Patel Y, Hodsdon P, Baines JP, Blakely EL, Polke J, Taylor RW, Fratter C. (2023). Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. European journal of human genetics : EJHG. open_in_new
Findings: m.3243A>G may decline in blood with age; urine can improve detection. Assay sensitivity and clinical suspicion guide sample selection. Muscle biopsy is no longer routine first-line testing.
Population: People investigated for mitochondrial disease
Limits: Guideline; laboratory methods, age and clinical phenotype affect sensitivity.
Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove JL, Wolfe L, DiMauro S. (2015). Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: A Delphi-based consensus addresses diagnosis and treatment of mitochondrial disease.
Population: Mitochondrial Medicine Society expert panel
Limits: Only abstract assessed here; use separately assessed current/full-text sources for detailed recommendations.
McCormick EM, Lott MT, Dulik MC, Shen L, Attimonelli M, Vitale O, Karaa A, Bai R, Pineda-Alvarez DE, Singh LN, Stanley CM, Wong S, Bhardwaj A, Merkurjev D, Mao R, Sondheimer N, Zhang S, Procaccio V, Wallace DC, Gai X, Falk MJ. (2020). Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. Human mutation. open_in_new
Findings: Adapts ACMG/AMP evidence criteria to mtDNA heteroplasmy, inheritance, haplogroups and functional studies.
Population: ClinGen expert specifications for mtDNA variant interpretation
Limits: Variant classification guidance is not a personal severity or prognosis tool.
McDonnell MT, Schaefer AM, Blakely EL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. (2004). Noninvasive diagnosis of the 3243A > G mitochondrial DNA mutation using urinary epithelial cells. European journal of human genetics : EJHG. open_in_new
Findings: Urinary epithelial heteroplasmy correlated with muscle load, supporting urine as a useful non-invasive diagnostic sample.
Population: 18 m.3243A>G patients with muscle, blood and urine samples
Limits: Small diagnostic comparison; urine levels are not an exact whole-body measure or prognosis.
Whittaker RG, Blackwood JK, Alston CL, Blakely EL, Elson JL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. (2009). Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. Neurology. open_in_new
Findings: Bibliographic record verified; no abstract available in the retrieved record. Full text must be assessed before using this source to support a claim.
Population: Not yet extracted
Limits: No findings assessed. Title alone is not evidence.
de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. (2012). Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. Journal of inherited metabolic disease. open_in_new
Findings: Reports variable features and tissue/age-dependent heteroplasmy, supporting urinary epithelial testing.
Population: 34 Dutch families, 82 carriers among 127 participants
Limits: Related family members and selected cohort; contains a correction and cannot define individual severity.
Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. open_in_new
Findings: Age and tissue affect heteroplasmy measurements. Relationships with disease burden are useful at cohort level but do not precisely predict one person’s course.
Population: m.3243A>G cohort; blood 231, urine 235, muscle 77
Limits: Observational tissue comparisons; cohorts overlap other UK reports.
Rajasimha HK, Chinnery PF, Samuels DC. (2008). Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood. American journal of human genetics. open_in_new
Findings: Models selection against m.3243A>G in blood stem-cell lineages and age-related decline in blood heteroplasmy.
Population: Human heteroplasmy data and haematopoietic simulations
Limits: Model-dependent correction; blood heteroplasmy is not whole-body load.
't Hart LM, Jansen JJ, Lemkes HH, de Knijff P, Maassen JA. (1996). Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging. Human mutation. open_in_new
Findings: Blood heteroplasmy declined in 17/18 over 1.5–6 years; oral mucosa had higher levels on average.
Population: 18 m.3243A>G carriers with repeated blood samples
Limits: Small longitudinal sample; the mean rate is not a patient-specific correction or evidence of improving disease.
Okazaki A, Yatsuka Y, Fushimi T, Onuki T, Aida Y, Aihara H, Imasawa T, Ohtake A, Murayama K, Okazaki Y. (2026). Non-invasive urinary heteroplasmy screening outperforms blood testing for certain mitochondrial DNA variants in mitochondrial disease patients. Molecular genetics and metabolism. open_in_new
Findings: Urinary heteroplasmy exceeded blood heteroplasmy in all 80 paired m.3243A>G samples, supporting complementary urinary testing.
Population: 164 genetically confirmed mitochondrial disease participants; 80 paired m.3243A>G blood/urine samples
Limits: Exploratory 10% threshold is not a diagnostic or prognostic cutoff; biopsy selection biases tissue comparisons.
Kong X, Bei L, Gao P, Lu L, Zhu H, Jiang Y, Zhao M, Liu Y, Wang G, Li M, Feng Z, Deng G, Cao Y, Ma L. (2026). Clinical Validation of Digital PCR for Precise m.3243A>G Heteroplasmy Quantification in Early-Onset Diabetes. Journal of diabetes research. open_in_new
Findings: Validated digital PCR detected low-level m.3243A>G heteroplasmy; urinary sediment complemented blood testing.
Population: 1506 Chinese Han people with early-onset diabetes
Limits: Assay performance depends on input and validation conditions; this selected population is not a general prevalence estimate.
Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, Õunap K, Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J, Rissanen A, Yki-Järvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H. (2011). FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. The Lancet. Neurology. open_in_new
Findings: FGF21 showed diagnostic discrimination especially in muscle-manifesting respiratory-chain disease.
Population: Adults and children with respiratory-chain disorders and disease/healthy controls
Limits: Phenotype-specific retrospective diagnostic study; normal values do not rule out all mitochondrial disease and biopsy-first framing is historical.
Lehtonen JM, Forsström S, Bottani E, Viscomi C, Baris OR, Isoniemi H, Höckerstedt K, Österlund P, Hurme M, Jylhävä J, Leppä S, Markkula R, Heliö T, Mombelli G, Uusimaa J, Laaksonen R, Laaksovirta H, Auranen M, Zeviani M, Smeitink J, Wiesner RJ, Nakada K, Isohanni P, Suomalainen A. (2016). FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. Neurology. open_in_new
Findings: FGF21 and GDF15 sensitivity differs by disease mechanism; GDF15 also rises in nonmitochondrial conditions.
Population: Human biomarker cohorts, meta-analysis and six mouse models
Limits: Phenotype-specific performance; normal markers do not exclude mitochondrial disease.
Koene S, de Laat P, van Tienoven DH, Weijers G, Vriens D, Sweep FC, Timmermans J, Kapusta L, Janssen MC, Smeitink JA. (2015). Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers. JIMD reports. open_in_new
Findings: GDF15 correlated with baseline burden but did not track disease progression reliably.
Population: 97 adult m.3243A>G carriers; 49 followed for two years
Limits: Observational associations and small cardiac subset; biomarker is not a validated individual progression measure.
Davis RL, Kumar KR, Puttick C, Liang C, Ahmad KE, Edema-Hildebrand F, Park JS, Minoche AE, Gayevskiy V, Mallawaarachchi AC, Christodoulou J, Schofield D, Dinger ME, Cowley MJ, Sue CM. (2022). Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis. Neurology. open_in_new
Findings: Bigenomic whole-genome sequencing produced a molecular diagnosis in 53.7% of the selected cohort.
Population: 242 adults attending a specialist mitochondrial clinic
Limits: Referral and clinical selection determine yield; blood testing can still have tissue-specific limitations.
Wortmann SB, Koolen DA, Smeitink JA, van den Heuvel L, Rodenburg RJ. (2015). Whole exome sequencing of suspected mitochondrial patients in clinical practice. Journal of inherited metabolic disease. open_in_new
Findings: Whole-exome testing identified molecular diagnoses in 39% of this heterogeneous referral cohort, including mimicking conditions.
Population: 109 patients with suspected mitochondrial disorders
Limits: Historical technology and referral mix determine yield; does not guarantee diagnosis in an individual.
Mitochondrial Medicine Society's Committee on Diagnosis, Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Wong LJ, Cohen BH, Naviaux RK. (2008). The in-depth evaluation of suspected mitochondrial disease. Molecular genetics and metabolism. open_in_new
Findings: Describes integrating clinical, biochemical, tissue and genetic evidence for diagnosis.
Population: Mitochondrial Medicine Society diagnostic review
Limits: Historical diagnostic methods; newer guidance places greater emphasis on genomics.
Grier J, Hirano M, Karaa A, Shepard E, Thompson JLP. (2018). Diagnostic odyssey of patients with mitochondrial disease: Results of a survey. Neurology. Genetics. open_in_new
Findings: Survey participants described multiple consultations and alternative diagnoses before a mitochondrial diagnosis.
Population: 210 registry respondents: patients with biochemical deficiency or self-reported diagnosis, or caregivers
Limits: Self-selected retrospective survey; not all molecularly confirmed and not a current waiting-time estimate.
Varga L, Borecka S, Skopkova M, Rambani V, Sklenar M, Cipkova K, Kickova T, Ugorova D, Kabatova Z, Stanik J, Profant M, Gasperikova D. (2026). Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients. Ear and hearing. open_in_new
Findings: Cochlear implantation produced useful long-term hearing outcomes in three individuals in the reported m.3243A>G series.
Population: m.3243A>G cases identified during Slovak hearing-loss screening
Limits: Small selected implant series; outcome varies and requires specialist assessment.
Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: A UK cohort showed MELAS, MIDD, overlap, PEO, isolated manifestations and clinically asymptomatic carriers.
Population: 129 people from 83 families in a UK mitochondrial cohort
Limits: Clinical and family ascertainment; percentages are not population prevalence or future risk.
Care and emergencies
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF. (2017). Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: Uses expert Delphi consensus to organise routine care of primary mitochondrial disease.
Population: Mitochondrial Medicine Society care consensus
Limits: Abstract only here; detailed site recommendations use the assessed full-text Australian adaptation and newer topic guidance.
Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove JL, Wolfe L, DiMauro S. (2015). Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: A Delphi-based consensus addresses diagnosis and treatment of mitochondrial disease.
Population: Mitochondrial Medicine Society expert panel
Limits: Only abstract assessed here; use separately assessed current/full-text sources for detailed recommendations.
Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. open_in_new
Findings: Baseline and periodic audiology, hearing aids and assessment for cochlear implantation are recommended. Baseline cardiac assessment and ongoing monitoring are recommended; annual ECG and individualised other cardiac testing are advised. Endocrine surveillance is recommended; metformin is discouraged as first-line therapy because of concern about lactic acidosis. Care includes nutritional, swallowing, renal, neurological, eye and psychosocial assessment tailored to manifestations. A written emergency plan should include diagnosis, baseline organ function, special nutritional needs, medicines, allergies, contraindicated treatments and specialist contacts. Acute management depends on clinical assessment. Balanced nutrition, individual dietitian advice and treatment of specific deficiencies are recommended. Evidence for routine supplements or ketogenic/high-fat diets is limited. Assess worsening fatigue for treatable causes and tailor physical activity with an appropriate professional, considering cardiac involvement.
Population: Primary mitochondrial disease
Limits: Consensus; no single intensity, heart-rate target or recovery cut-off fits every person.
Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. open_in_new
Findings: MELAS is a clinical syndrome including stroke-like episodes associated with pathogenic mtDNA; the m.3243A>G variant alone does not establish MELAS. New stroke-like symptoms require urgent assessment and suspected seizures need prompt treatment. Efficacy of arginine, citrulline, taurine and routine supplements remains unproven.
Population: MELAS / stroke-like episodes
Limits: Consensus based on limited therapeutic evidence; no self-treatment regimen follows from these statements.
Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, Martikainen MH, Mcfarland R, Nesbitt V, Pitceathly RDS, Schaefer AM, Turnbull DM. (2019). Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome open research. open_in_new
Findings: Frames stroke-like episodes as an epileptic encephalopathy and prioritises early seizure management.
Population: European expert consensus on stroke-like episodes
Limits: Expert consensus with acknowledged lack of randomised treatment evidence; compare 2026 update.
Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. open_in_new
Findings: Valproate is contraindicated in POLG disease and hepatic-risk settings; use in non-POLG disease without liver impairment requires individual specialist judgement.
Population: Primary mitochondrial diseases; POLG exception explicit
Limits: Expert consensus; absence of a contraindication does not prove universal safety.
De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti C, McFarland R, Ng YS, O'Callaghan M, Pitceathly RDS, Rahman S, Russel FGM, Varhaug KN, Schirris TJJ, Mancuso M. (2020). Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus. Journal of inherited metabolic disease. open_in_new
Findings: Severe genotype-specific aminoglycoside ototoxicity risk is particularly associated with MT-RNR1 variants; m.3243A>G should not be equated with those variants. Infection severity and individual risks matter. Linezolid may be used when needed, with careful lactate monitoring in susceptible patients; mitochondrial toxicity is a context-dependent risk rather than a universal prohibition. Anaesthetic risk depends on agent, duration, illness and organ involvement. Short propofol induction is distinguished from prolonged infusion. Statins are not universally contraindicated in primary mitochondrial disease; monitor muscle symptoms and CK according to guidance. Consensus distinguishes topical chloramphenicol and tetracyclines from blanket mitochondrial drug prohibitions. The consensus discourages excessive alcohol but does not establish universal toxicity from any small amount in all mitochondrial disease.
Population: Primary mitochondrial diseases
Limits: Expert opinion; seizures, liver disease, diabetes, interactions and pregnancy may require stricter advice.
Demczko MM, Ganetzky RD, Tormey C, Ku BC, Blowey B, Lavelle J, Goldstein A. (2025). Improving acute care for Primary Mitochondrial Disease: Development of a publicly available clinical care pathway. Molecular genetics and metabolism. open_in_new
Findings: Describes a publicly available pathway based on expert consensus for emergency and inpatient mitochondrial care.
Population: Development of a paediatric acute-care pathway
Limits: Abstract describes pathway development; improved clinical outcomes are proposed, not demonstrated.
Niezgoda J, Morgan PG. (2013). Anesthetic considerations in patients with mitochondrial defects. Paediatric anaesthesia. open_in_new
Findings: Discusses perioperative metabolic stress, fasting, pain and anaesthetic considerations.
Population: Anaesthesia review across mitochondrial disorders
Limits: Heterogeneous disease and limited prospective evidence; no universal drug or fasting protocol.
Footitt EJ, Sinha MD, Raiman JA, Dhawan A, Moganasundram S, Champion MP. (2008). Mitochondrial disorders and general anaesthesia: a case series and review. British journal of anaesthesia. open_in_new
Findings: Retrospective review reported no attributed intraoperative events and three postoperative complications.
Population: 38 children, 58 anaesthetic exposures
Limits: Small retrospective heterogeneous series; does not prove all agents safe or eliminate perioperative risk.
Johnson BM, Johnson SC. (2026). Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports. Paediatric anaesthesia. open_in_new
Findings: Published cases described varied perianesthetic complications and associations with anesthetic type, symptoms and procedure length.
Population: 148 anesthetic cases from 123 reports in genetic mitochondrial disease
Limits: Case-report selection and confounding preclude absolute risk estimates, causal anesthetic comparisons or blanket drug recommendations.
Barcelos I, Shadiack E, Ganetzky RD, Falk MJ. (2020). Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines. Current opinion in pediatrics. open_in_new
Findings: Cofactors are used for selected indications; biochemical plausibility and experience exceed the available trial evidence for many routine supplement combinations. NAC is discussed on the basis of preclinical antioxidant evidence; this does not establish clinical benefit for m.3243A>G.
Population: Review of mitochondrial therapies including animal-model evidence
Limits: Preclinical evidence and expert experience; genotype-specific clinical efficacy unresolved.
Murphy R, Turnbull DM, Walker M, Hattersley AT. (2008). Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabetic medicine : a journal of the British Diabetic Association. open_in_new
Findings: Summarises phenotype, diagnostic clues, prevalence literature and management considerations.
Population: MIDD clinical review
Limits: Historical review; current medication and genetic guidance can differ.
Hui L, Hayman P, Buckland A, Fahey MC, Mackey DA, Mallett AJ, Schweitzer DR, Stuart CP, Yau WY, Christodoulou J. (2025). Pregnancy in women with mitochondrial disease-A literature review and suggested guidance for preconception and pregnancy care. The Australian & New Zealand journal of obstetrics & gynaecology. open_in_new
Findings: Pregnancy outcomes vary; a review recommends coordinated preconception, antenatal, delivery and postnatal care, including organ assessment and medication review.
Population: Five cohorts and 19 case reports covering mitochondrial disease pregnancies
Limits: Small heterogeneous, often retrospective reports; complication percentages are not individual predictions.
Wahbi K, Bougouin W, Béhin A, Stojkovic T, Bécane HM, Jardel C, Berber N, Mochel F, Lombès A, Eymard B, Duboc D, Laforêt P. (2015). Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. European heart journal. open_in_new
Findings: Long-term retrospective cardiac study identified baseline features associated with major cardiac events.
Population: 260 adults with mixed mitochondrial genotypes, including 64 m.3243A>G
Limits: Heterogeneous referral cohort and composite endpoint; rates are not general carrier risks.
Diamond T, DiVito D, Savoca M, Mascarenhas M, Goldstein A. (2022). Nutrition rehabilitation-related complications in primary mitochondrial disorders. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. open_in_new
Findings: Reports important complications during enteral nutritional rehabilitation.
Population: Three young patients with different mitochondrial disorders
Limits: Selected adverse-event cases, none established as m.3243A>G in the abstract; cannot estimate complication incidence.
Finsterer J, Frank M. (2017). Gastrointestinal manifestations of mitochondrial disorders: a systematic review. Therapeutic advances in gastroenterology. open_in_new
Findings: Describes diverse digestive manifestations and largely symptom-directed care.
Population: Systematic review of GI manifestations across mitochondrial disorders
Limits: Heterogeneous conditions; rare manifestations and historical treatment assertions need disease-specific checking.
Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH. (2007). Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. open_in_new
Findings: Describes heterogeneous presentation and the absence of a single diagnostic biomarker.
Population: Paediatric mitochondrial disease review
Limits: Historical primary-care approach; current genomic guidance should drive testing.
Muraresku CC, McCormick EM, Falk MJ. (2018). Mitochondrial Disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies. Current genetic medicine reports. open_in_new
Findings: Summarises evolving genomic diagnosis, phenotype-specific care and experimental approaches.
Population: Review of diagnosis, management and reproductive strategies
Limits: Historical narrative synthesis; verify current regulatory and trial status separately.
Dalili S, Rostampour N, Mousavi ST, Joni SS, Mahdieh N, Rad AH, Hakemzadeh ST, Nikpour S, Talea A, Moravvej H. (2025). Comprehensive Iranian guidelines for the diagnosis and management of mitochondrial disorders: an evidence- and consensus-based approach. Orphanet journal of rare diseases. open_in_new
Findings: Guidance combines literature from 2000–2023 with context-specific diagnostic and management recommendations.
Population: Iranian multidisciplinary consensus on mitochondrial disorders
Limits: Abstract describes development, not recommendation details or comparative outcomes; full guidance needed before applying protocols.
Medication safety
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti C, McFarland R, Ng YS, O'Callaghan M, Pitceathly RDS, Rahman S, Russel FGM, Varhaug KN, Schirris TJJ, Mancuso M. (2020). Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus. Journal of inherited metabolic disease. open_in_new
Findings: Severe genotype-specific aminoglycoside ototoxicity risk is particularly associated with MT-RNR1 variants; m.3243A>G should not be equated with those variants. Infection severity and individual risks matter. Linezolid may be used when needed, with careful lactate monitoring in susceptible patients; mitochondrial toxicity is a context-dependent risk rather than a universal prohibition. Anaesthetic risk depends on agent, duration, illness and organ involvement. Short propofol induction is distinguished from prolonged infusion. Statins are not universally contraindicated in primary mitochondrial disease; monitor muscle symptoms and CK according to guidance. Consensus distinguishes topical chloramphenicol and tetracyclines from blanket mitochondrial drug prohibitions. The consensus discourages excessive alcohol but does not establish universal toxicity from any small amount in all mitochondrial disease.
Population: Primary mitochondrial diseases
Limits: Expert opinion; seizures, liver disease, diabetes, interactions and pregnancy may require stricter advice.
Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. open_in_new
Findings: Valproate is contraindicated in POLG disease and hepatic-risk settings; use in non-POLG disease without liver impairment requires individual specialist judgement.
Population: Primary mitochondrial diseases; POLG exception explicit
Limits: Expert consensus; absence of a contraindication does not prove universal safety.
Ratnaike TE, Elkhateeb N, Lochmüller A, Gilmartin C, Schon K, Horváth R, Chinnery PF. (2024). Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis. BMJ neurology open. open_in_new
Findings: A systematic patient-level analysis found substantially stronger evidence of fatal valproate toxicity in POLG disease than in mtDNA disease.
Population: 156 patients from 90 publications; 35 with mtDNA disease
Limits: Published case data; small non-POLG samples and reporting bias preclude assurances of safety.
Järvinen O, Martikainen MH. (2026). Drug safety in patients with mitochondrial disease: an observational cohort study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. open_in_new
Findings: Medication records identified potential mitochondrial toxicity concerns and a need for better drug safety evidence and attention to pain.
Population: 44 predominantly adult mitochondrial disease patients at one Finnish centre
Limits: Potential toxicity and prescribing records are not demonstrated causal harm; retrospective mixed-genotype single-centre study.
Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. open_in_new
Findings: MELAS is a clinical syndrome including stroke-like episodes associated with pathogenic mtDNA; the m.3243A>G variant alone does not establish MELAS. New stroke-like symptoms require urgent assessment and suspected seizures need prompt treatment. Efficacy of arginine, citrulline, taurine and routine supplements remains unproven.
Population: MELAS / stroke-like episodes
Limits: Consensus based on limited therapeutic evidence; no self-treatment regimen follows from these statements.
Niezgoda J, Morgan PG. (2013). Anesthetic considerations in patients with mitochondrial defects. Paediatric anaesthesia. open_in_new
Findings: Discusses perioperative metabolic stress, fasting, pain and anaesthetic considerations.
Population: Anaesthesia review across mitochondrial disorders
Limits: Heterogeneous disease and limited prospective evidence; no universal drug or fasting protocol.
Footitt EJ, Sinha MD, Raiman JA, Dhawan A, Moganasundram S, Champion MP. (2008). Mitochondrial disorders and general anaesthesia: a case series and review. British journal of anaesthesia. open_in_new
Findings: Retrospective review reported no attributed intraoperative events and three postoperative complications.
Population: 38 children, 58 anaesthetic exposures
Limits: Small retrospective heterogeneous series; does not prove all agents safe or eliminate perioperative risk.
Johnson BM, Johnson SC. (2026). Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports. Paediatric anaesthesia. open_in_new
Findings: Published cases described varied perianesthetic complications and associations with anesthetic type, symptoms and procedure length.
Population: 148 anesthetic cases from 123 reports in genetic mitochondrial disease
Limits: Case-report selection and confounding preclude absolute risk estimates, causal anesthetic comparisons or blanket drug recommendations.
Chaudhry A, Thompson DM, Chanoine JP. (2026). Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm. Diabetes, obesity & metabolism. open_in_new
Findings: Treatment is individualised to insulin reserve, glucose control, nutrition and organ disease. Authors propose several agents, including conditional metformin use; no MIDD-specific randomised treatment trials establish a preferred sequence.
Population: MIDD; recommendations partly extrapolated from type 2 diabetes
Limits: Proposed algorithm, not a validated guideline; direct MIDD drug comparisons are lacking.
Santhosh T, Ramamurthy P, Simha V. (2025). Safe Use of Metformin in Mitochondrial Diabetes in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes: Insights From a Patient With m.3243A>G Mutation. AACE endocrinology and diabetes. open_in_new
Findings: Metformin reintroduction improved glucose control without lactate elevation or new neurological symptoms in this monitored case.
Population: One 49-year-old man with m.3243A>G diabetes
Limits: Single case cannot establish general safety; balance against adverse-event reports and guidance.
Shin HJ, Na JH, Lee YM. (2024). A case of exacerbated encephalopathy with stroke-like episodes and lactic acidosis triggered by metformin in a patient with MELAS. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. open_in_new
Findings: Reports stroke-like episodes and lactic acidosis associated with metformin exposure.
Population: One 32-year-old Korean patient with MELAS
Limits: Single adverse-event report; cannot establish incidence, universal contraindication or the introductory diabetes prevalence claim.
Lin WH, Yang IH, Cheng HE, Lin HF. (2022). Case Report: Late-Onset Mitochondrial Disease Uncovered by Metformin Use in a Patient With Acute Verbal Auditory Agnosia. Frontiers in neurology. open_in_new
Findings: Neurological symptoms and raised lactate improved after metformin discontinuation in a reported case.
Population: One 43-year-old m.3243A>G patient after starting diabetes treatment
Limits: Temporal association with competing causes and co-treatment; cannot estimate incidence or establish universal causality.
Ryytty S, Nurminen K, Mäkinen P, Suomalainen A, Hämäläinen RH. (2025). Heightened sensitivity to adverse effects of metformin in mtDNA mutant patient cells. Life sciences. open_in_new
Findings: Metformin effects differed by concentration, mutation load and patient cell line.
Population: iPSCs from two m.3243A>G patients and derived cardiomyocytes
Limits: In-vitro exposure and patient-specific effects; not proof of clinical safety or a universal drug ban.
Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. (1997). Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. European journal of pediatrics. open_in_new
Findings: A case described worsening convulsions during valproate therapy followed by MELAS diagnosis.
Population: One m.3243A>G patient exposed to valproate
Limits: Single adverse-event report supports caution but cannot define incidence or a genotype-wide contraindication; compare current consensus and POLG-specific risks.
Hynynen J, Komulainen T, Tukiainen E, Nordin A, Arola J, Kälviäinen R, Jutila L, Röyttä M, Hinttala R, Majamaa K, Mäkisalo H, Uusimaa J. (2014). Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. open_in_new
Findings: Reports genotype-specific liver toxicity and variable outcomes after transplantation.
Population: Five POLG-associated valproate liver-failure cases
Limits: Small retrospective POLG series; not evidence of the same risk magnitude in MT-TL1 disease.
Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D. (2000). Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver. open_in_new
Findings: A family report describes fatal liver failure after valproate exposure in a suspected mitochondrial disorder.
Population: Three siblings with suspected mitochondrial cytopathy; one valproate-exposed adult
Limits: Genetic cause was not established; cannot infer an m.3243A>G-specific absolute prohibition.
Finsterer J, Zarrouk Mahjoub S. (2012). Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert opinion on drug metabolism & toxicology. open_in_new
Findings: Discusses mitochondrial toxicity concerns, including strong valproate concern in POLG disease.
Population: Review of antiseizure medicines in mitochondrial disease
Limits: Historical broad cautions; compare newer 2024 seizure consensus and genotype-specific evidence.
Lim A, Thomas RH. (2020). The mitochondrial epilepsies. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. open_in_new
Findings: Describes varied seizure presentations, specialist management and substantial valproate concern in POLG disease.
Population: Review of mitochondrial epilepsies
Limits: Narrative review; exact medicine choices require newer genotype-specific guidance.
Kam PC, Cardone D. (2007). Propofol infusion syndrome. Anaesthesia. open_in_new
Findings: The review describes serious metabolic and cardiac complications associated especially with high-dose or prolonged propofol exposure.
Population: Literature review of 61 propofol infusion syndrome cases
Limits: General PRIS case literature; dose-duration associations do not define a universally safe threshold in mitochondrial disease.
Finsterer J, Segall L. (2010). Drugs interfering with mitochondrial disorders. Drug and chemical toxicology. open_in_new
Findings: Lists potential mitochondrial effects of multiple drug classes.
Population: Historical medication review
Limits: Broad cautions are not equivalent to clinical contraindications; newer drug-specific consensus permits several listed medicines.
Supplements and adjunctive treatments
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. open_in_new
Findings: MELAS is a clinical syndrome including stroke-like episodes associated with pathogenic mtDNA; the m.3243A>G variant alone does not establish MELAS. New stroke-like symptoms require urgent assessment and suspected seizures need prompt treatment. Efficacy of arginine, citrulline, taurine and routine supplements remains unproven.
Population: MELAS / stroke-like episodes
Limits: Consensus based on limited therapeutic evidence; no self-treatment regimen follows from these statements.
Stefanetti RJ, Ng YS, Errington L, Blain AP, McFarland R, Gorman GS. (2022). l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review. Neurology. open_in_new
Findings: No randomised trials were found among 37 reports involving 91 people. Study quality and concurrent treatments prevent confident attribution of benefit to IV or oral arginine.
Population: 91 people; most had m.3243A>G
Limits: Very low quality evidence, uncontrolled reports and co-interventions; efficacy remains unresolved.
Argudo JM, Astudillo Moncayo OM, Insuasti W, Garofalo G, Aguirre AS, Encalada S, Villamarin J, Oña S, Tenemaza MG, Eissa-Garcés A, Matcheswalla S, Ortiz JF. (2022). Arginine for the Treatment of Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes: A Systematic Review. Cureus. open_in_new
Findings: The review interprets arginine reports favourably for acute and preventive use.
Population: Systematic review restricted to four full-text English-language arginine studies
Limits: Restricted evidence selection and uncontrolled studies; conclusion conflicts with broader systematic review and newer consensus.
Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. (2018). Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. Journal of neurology. open_in_new
Findings: Small prospective Japanese oral and IV studies reported symptom and episode-related signals with arginine.
Population: 15 oral-treatment and 10 IV-treatment participants
Limits: No randomised comparator; small cohorts; natural variation and other treatments complicate attribution.
Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y, KN01 Study Group. (2019). Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: Ten people received high-dose taurine in a 52-week open-label trial; fewer episodes were reported, but no placebo comparison establishes causality.
Population: 10 people with MELAS and recurrent stroke-like episodes
Limits: Uncontrolled small study, wide confidence intervals; not proof of prevention or general m.3243A>G benefit.
Almannai M, Duong J, El-Hattab AW, Ali M, Bauri D, Hawk N, Soler-Alfonso C, Delay L, Chu ZD, Liu N, Gijavanekar C, Elsea SH, Kralik SP, Lee S, Scaglia F. (2026). L-citrulline treatment of nitric oxide deficiency in MELAS a phase I dose-finding and safety study. Molecular genetics and metabolism. open_in_new
Findings: A ten-person phase I study assessed tolerability and biochemical/cerebral blood-flow changes; efficacy requires randomised testing. Higher-dose guanidino signals need further safety study.
Population: 10 adults with MELAS
Limits: Small short dose-finding study; no clinical efficacy comparison or long-term safety assurance.
El-Hattab AW, Hsu JW, Emrick LT, Wong LJ, Craigen WJ, Jahoor F, Scaglia F. (2012). Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Molecular genetics and metabolism. open_in_new
Findings: Arginine and citrulline raised nitric oxide production in a metabolic study, with a greater biochemical effect from citrulline.
Population: People with MELAS compared with controls
Limits: Surrogate metabolic outcomes; not a trial proving fewer stroke-like episodes.
Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, Fujimoto S, Matsuishi T. (2005). L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. open_in_new
Findings: An early report described symptom improvements with arginine administration.
Population: MELAS patients receiving acute or interictal arginine; sample size not specified in abstract
Limits: Abstract leaves important design details unclear; later systematic review finds no established efficacy. Do not adopt its timing claims as a protocol.
Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, Ishii M, Matsuishi T. (2006). Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology. open_in_new
Findings: Flow-mediated vasodilation improved during oral arginine supplementation in an early physiological study.
Population: MELAS patients studied for endothelial function; sample size absent from abstract
Limits: Surrogate vascular outcome; clinical prevention of stroke-like episodes is not established.
Rodan LH, Poublanc J, Fisher JA, Sobczyk O, Mikulis DJ, Tein I. (2020). L-arginine effects on cerebrovascular reactivity, perfusion and neurovascular coupling in MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) syndrome. PloS one. open_in_new
Findings: Arginine was associated with regional perfusion and reactivity changes, while global reactivity was unchanged.
Population: Three m.3243A>G MELAS siblings in arginine pilot
Limits: Tiny related sample and imaging surrogates; cannot establish prevention of stroke-like episodes.
Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. (2010). A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle & nerve. open_in_new
Findings: A small randomised trial found limited effects of CoQ10 on selected exercise measures and no broad improvement across clinical outcomes.
Population: 30 people with mitochondrial cytopathy
Limits: Short study, mixed disease population; not evidence of prevention of MIDD progression.
Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. (2007). Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle & nerve. open_in_new
Findings: A small crossover trial of creatine, CoQ10 and lipoic acid found changes in surrogate measures; attribution to one ingredient and functional benefit remain uncertain.
Population: 16 people with mixed mitochondrial cytopathies, including three with MELAS
Limits: Small heterogeneous combination trial, surrogate outcomes; larger functional/QoL studies needed.
Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. (2012). Treatment for mitochondrial disorders. The Cochrane database of systematic reviews. open_in_new
Findings: A Cochrane review found no clear overall benefit across the small heterogeneous trials of mitochondrial therapies available at that time.
Population: 12 trials of mixed mitochondrial disorders in the 2012 review
Limits: Historical evidence review; does not assess all later therapies or prove that every supplement is ineffective.
Barcelos I, Shadiack E, Ganetzky RD, Falk MJ. (2020). Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines. Current opinion in pediatrics. open_in_new
Findings: Cofactors are used for selected indications; biochemical plausibility and experience exceed the available trial evidence for many routine supplement combinations. NAC is discussed on the basis of preclinical antioxidant evidence; this does not establish clinical benefit for m.3243A>G.
Population: Review of mitochondrial therapies including animal-model evidence
Limits: Preclinical evidence and expert experience; genotype-specific clinical efficacy unresolved.
Pirinen E, Auranen M, Khan NA, Brilhante V, Urho N, Pessia A, Hakkarainen A, Kuula J, Heinonen U, Schmidt MS, Haimilahti K, Piirilä P, Lundbom N, Taskinen MR, Brenner C, Velagapudi V, Pietiläinen KH, Suomalainen A. (2020). Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. Cell metabolism. open_in_new
Findings: Niacin increased NAD-related measures and muscle performance in a selected adult-onset myopathy study; an anaemia tendency was noted.
Population: Adult-onset mitochondrial myopathy patients and matched controls
Limits: Small non-randomised study of a selected phenotype; not a routine recommendation for all m.3243A>G carriers.
Suzuki T, Suzuki T, Wada T, Saigo K, Watanabe K. (2002). Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. The EMBO journal. open_in_new
Findings: Taurine-containing uridine modifications were identified in mitochondrial tRNAs; pathogenic MELAS/MERRF cells can lack these modifications.
Population: Biochemical and cellular work on mitochondrial tRNAs
Limits: Mechanistic evidence does not establish that oral taurine improves clinical outcomes.
Suzuki S, Hinokio Y, Ohtomo M, Hirai M, Hirai A, Chiba M, Kasuga S, Satoh Y, Akai H, Toyota T. (1998). The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia. open_in_new
Findings: Three-year study reported preserved insulin secretion and hearing measures in treated MIDD participants, without effects on other complications.
Population: 50 CoQ10-treated m.3243A>G carriers and 26 comparison carriers with differing glucose tolerance
Limits: Abstract does not report randomization or blinding; older nonrandomized comparison cannot establish efficacy or justify routine dosing.
Marshall RP, Droste JN, Giessing J, Kreider RB. (2022). Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A Narrative Review. Nutrients. open_in_new
Findings: Discusses potential bioenergetic and protective mechanisms of creatine.
Population: Narrative review of creatine across mitochondrial dysfunction-related conditions
Limits: Broad conditions include secondary dysfunction and injury; not direct evidence for routine m.3243A>G supplementation.
Almannai M, El-Hattab AW. (2021). Nitric Oxide Deficiency in Mitochondrial Disorders: The Utility of Arginine and Citrulline. Frontiers in molecular neuroscience. open_in_new
Findings: Summarises arginine reports and stronger citrulline-related NO synthesis signals while calling for controlled trials.
Population: Review of nitric oxide biology and precursor supplementation
Limits: Mechanistic and uncontrolled evidence; biochemical improvement does not establish clinical efficacy.
Hargreaves IP. (2014). Coenzyme Q10 as a therapy for mitochondrial disease. The international journal of biochemistry & cell biology. open_in_new
Findings: Discusses CoQ10 biology and its established relevance to primary CoQ10 biosynthetic defects.
Population: CoQ10 treatment review
Limits: Review language about broader benefit exceeds what limited controlled trials establish for m.3243A>G.
Nutrition
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
DiVito D, Wellik A, Burfield J, Peterson J, Flickinger J, Tindall A, Albanowski K, Vishnubhatt S, MacMullen L, Martin I, Muraresku C, McCormick E, George-Sankoh I, McCormack S, Goldstein A, Ganetzky R, Yudkoff M, Xiao R, Falk MJ, R Mascarenhas M, Zolkipli-Cunningham Z. (2023). Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of Life. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. open_in_new
Findings: In a 60-person cohort, inadequate intake and malnutrition occurred, and nutrient intake correlated with some muscle and quality-of-life measures.
Population: 22 adults and 38 children with genetically confirmed primary mitochondrial disease; exclusively tube-fed people excluded
Limits: Observational correlations and estimated energy requirements; does not prove that a specific diet improves outcomes.
de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. (2015). Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. The Netherlands journal of medicine. open_in_new
Findings: Swallowing and gastrointestinal problems, including constipation, can contribute to malnutrition in m.3243A>G disease.
Population: 92 m.3243A>G carriers
Limits: Observational cohort; symptom burden varies; no tested dietary prescription.
Zweers H, Janssen MCH, Leij S, Wanten G. (2018). Patients With Mitochondrial Disease Have an Inadequate Nutritional Intake. JPEN. Journal of parenteral and enteral nutrition. open_in_new
Findings: Diet diaries showed frequent inadequate intake with large individual differences, supporting individual nutritional assessment.
Population: 60 three-day nutrition diaries from adults with mitochondrial disease
Limits: Retrospective dietary data and population comparisons; not a trial of specific foods.
Aubry E, Aeberhard C, Bally L, Nuoffer JM, Risch L, Mühlebach S, Burgunder JM, Stanga Z. (2018). Are patients affected by mitochondrial disorders at nutritional risk? Nutrition (Burbank, Los Angeles County, Calif.). open_in_new
Findings: Detailed assessment identified low protein intake, muscle mass and other nutritional concerns missed by a screening score.
Population: 11 mitochondrial outpatients and 15 controls
Limits: Small selected cohort; cannot infer universal malnutrition or prove benefit from a specific protein target.
Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM, Falk MJ, Goldstein AC, Gopal-Srivastava R, Gorman GS, Hersh SP, Hirano M, Hoffman FA, Karaa A, MacLeod EL, McFarland R, Mohan C, Mulberg AE, Odenkirchen JC, Parikh S, Rutherford PJ, Suggs-Anderson SK, Tang WH, Vockley J, Wolfe LA, Yannicelli S, Yeske PE, Coates PM. (2016). Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Molecular genetics and metabolism. open_in_new
Findings: Identifies evidence gaps, limited controlled supplement trials and priorities for nutritional research.
Population: NIH workshop on nutrition in primary mitochondrial disorders
Limits: Workshop consensus and research agenda, not proof of supplement efficacy.
Diamond T, DiVito D, Savoca M, Mascarenhas M, Goldstein A. (2022). Nutrition rehabilitation-related complications in primary mitochondrial disorders. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. open_in_new
Findings: Reports important complications during enteral nutritional rehabilitation.
Population: Three young patients with different mitochondrial disorders
Limits: Selected adverse-event cases, none established as m.3243A>G in the abstract; cannot estimate complication incidence.
Houghton D, Ng YS, Jackson MA, Stefanetti R, Hynd P, Mac Aogáin M, Stewart CJ, Lamb CA, Bright A, Feeney C, Newman J, Turnbull DM, McFarland R, Blain AP, Gorman GS. (2022). Phase II Feasibility Study of the Efficacy, Tolerability, and Impact on the Gut Microbiome of a Low-Residue (Fiber) Diet in Adult Patients With Mitochondrial Disease. Gastro hep advances. open_in_new
Findings: A 12-week single-arm low-residue diet study reported tolerability and improvements in selected bowel symptoms, without improvement in colonic transit or stool frequency.
Population: 28 adults with mtDNA-related disease and constipation; 24 completed
Limits: Uncontrolled feasibility study; does not justify low-fibre diets for all dysmotility or swallowing problems.
Nielsen SR, Stoico MP, Liao D, Drewes AM, Pedersen IS, Frederiksen AL, Brock C. (2025). Prolonged Gastrointestinal Transit Times and Dysmotility in m.3243A>G Mitochondrial Disease. Neurogastroenterology and motility. open_in_new
Findings: Measured gastric and colonic transit abnormalities did not correlate with perceived GI symptom scores.
Population: 22 Danish m.3243A>G carriers and 22 matched controls
Limits: Small selected cohort; physiological measures alone do not dictate an individual diet or symptom explanation.
Finsterer J, Frank M. (2017). Gastrointestinal manifestations of mitochondrial disorders: a systematic review. Therapeutic advances in gastroenterology. open_in_new
Findings: Describes diverse digestive manifestations and largely symptom-directed care.
Population: Systematic review of GI manifestations across mitochondrial disorders
Limits: Heterogeneous conditions; rare manifestations and historical treatment assertions need disease-specific checking.
Zweers H, van Wegberg AMJ, Janssen MCH, Wortmann SB. (2021). Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety. Orphanet journal of rare diseases. open_in_new
Findings: A systematic review found sparse, heterogeneous evidence for ketogenic diets; some seizure responses were reported and muscle injury occurred in deletion-related myopathy.
Population: 20 genetically confirmed cases; predominantly case reports
Limits: Highly selected cases, variable genotypes and outcomes; specialist monitoring is required.
Huang L, Li H, Zhong J, Yang L, Chen G, Wang D, Zheng G, Han H, Han X, Long Y, Wang X, Liang J, Yu M, Shen X, Fan M, Fang F, Liao J, Sun D. (2022). Efficacy and Safety of the Ketogenic Diet for Mitochondrial Disease With Epilepsy: A Prospective, Open-labeled, Controlled Study. Frontiers in neurology. open_in_new
Findings: Open controlled study reported seizure reductions in some participants and dietary adverse effects.
Population: 33 participants assigned to ketogenic or delayed-diet groups
Limits: Semi-randomisation, short follow-up, small subgroups and open treatment limit safety/efficacy certainty.
Zweers HEE, Kroesen SH, Beerlink G, Buit E, Gerrits K, Dorhout A, van Wegberg AMJ, Janssen MCH, Wortmann SB, Timmers S, Saris CGJ. (2024). Ketogenic diet in adult patients with mitochondrial myopathy. Molecular genetics and metabolism. open_in_new
Findings: Only 8 of 20 participants completed a 12-week modified Atkins diet; adverse events included rhabdomyolysis and fatigue, with variable individual benefits.
Population: 20 adults with mitochondrial myopathy
Limits: Small uncontrolled heterogeneous study; m.3243A>G subgroup tolerance is not proof of safety or efficacy.
Ahola S, Auranen M, Isohanni P, Niemisalo S, Urho N, Buzkova J, Velagapudi V, Lundbom N, Hakkarainen A, Muurinen T, Piirilä P, Pietiläinen KH, Suomalainen A. (2016). Modified Atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy patients. EMBO molecular medicine. open_in_new
Findings: All five developed muscle pain and enzyme leakage within weeks, leading to diet discontinuation.
Population: Five adults with mitochondrial myopathy/PEO in modified Atkins pilot
Limits: Small selected cohort; later strength changes do not establish a safe regenerative diet strategy.
Wesół-Kucharska D, Greczan M, Kaczor M, Ehmke Vel Emczyńska-Seliga E, Hajdacka M, Czekuć-Kryśkiewicz E, Piekutowska-Abramczuk D, Halat-Wolska P, Ciara E, Jaworski M, Jezela-Stanek A, Rokicki D. (2024). Efficacy and Safety of Ketogenic Diet Treatment in Pediatric Patients with Mitochondrial Disease. Nutrients. open_in_new
Findings: Clinical improvement was reported in nine treated mitochondrial patients, with adverse events and no clear between-group biomarker difference.
Population: 42 children in four groups; 11 mitochondrial patients received ketogenic diet
Limits: Small non-randomised clinical groups; selection and heterogeneous outcomes limit conclusions.
Sakamoto N, Hamada S, Takahashi H, Satou R, Suzuki M, Maeno T. (2023). Improvement of Intestinal Pseudo-Obstruction by Total Parenteral Nutrition in a Young Woman With Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes: A Case Report. Cureus. open_in_new
Findings: Reports improvement after parenteral nutrition and subsequent glycaemic management.
Population: One 20-year-old woman with MELAS and intestinal pseudo-obstruction
Limits: Single case with multiple interventions; does not establish standard nutrition or diabetes-drug choices.
Horná S, Péč MJ, Krivuš J, Michalová R, Sivák Š, Galajda P, Mokáň M. (2024). Gastrointestinal Complications of Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome Managed By Parenteral Nutrition. European journal of case reports in internal medicine. open_in_new
Findings: Describes undernutrition, superior mesenteric artery syndrome and parenteral nutritional support.
Population: One young MELAS patient with severe GI complications
Limits: Single complex case; does not justify routine parenteral nutrition for all GI symptoms.
Vandana VP, Bindu PS, Sonam K, Taly AB, Gayathri N, Madhu N, Sinha S. (2015). Speech-Language and swallowing manifestations and rehabilitation in an 11-year-old girl with MELAS syndrome. Journal of pediatric neurosciences. open_in_new
Findings: Describes speech, language and swallowing assessment with six months of rehabilitation.
Population: One 11-year-old girl with MELAS
Limits: Single case; abstract does not establish the effectiveness of a specific intervention.
Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF. (2017). Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: Uses expert Delphi consensus to organise routine care of primary mitochondrial disease.
Population: Mitochondrial Medicine Society care consensus
Limits: Abstract only here; detailed site recommendations use the assessed full-text Australian adaptation and newer topic guidance.
Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. open_in_new
Findings: Baseline and periodic audiology, hearing aids and assessment for cochlear implantation are recommended. Baseline cardiac assessment and ongoing monitoring are recommended; annual ECG and individualised other cardiac testing are advised. Endocrine surveillance is recommended; metformin is discouraged as first-line therapy because of concern about lactic acidosis. Care includes nutritional, swallowing, renal, neurological, eye and psychosocial assessment tailored to manifestations. A written emergency plan should include diagnosis, baseline organ function, special nutritional needs, medicines, allergies, contraindicated treatments and specialist contacts. Acute management depends on clinical assessment. Balanced nutrition, individual dietitian advice and treatment of specific deficiencies are recommended. Evidence for routine supplements or ketogenic/high-fat diets is limited. Assess worsening fatigue for treatable causes and tailor physical activity with an appropriate professional, considering cardiac involvement.
Population: Primary mitochondrial disease
Limits: Consensus; no single intensity, heart-rate target or recovery cut-off fits every person.
Chaudhry A, Thompson DM, Chanoine JP. (2026). Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm. Diabetes, obesity & metabolism. open_in_new
Findings: Treatment is individualised to insulin reserve, glucose control, nutrition and organ disease. Authors propose several agents, including conditional metformin use; no MIDD-specific randomised treatment trials establish a preferred sequence.
Population: MIDD; recommendations partly extrapolated from type 2 diabetes
Limits: Proposed algorithm, not a validated guideline; direct MIDD drug comparisons are lacking.
Exercise, fatigue and rehabilitation
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J. (2006). Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain : a journal of neurology. open_in_new
Findings: Twelve weeks of supervised cycling improved exercise capacity in selected mitochondrial myopathy participants without measured increases in mutation load or injury markers.
Population: 20 mitochondrial myopathy patients with mixed mtDNA variants and 13 healthy participants
Limits: Small short study; supervised protocol in selected patients does not establish universal safety.
Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, Haller RG, Turnbull DM. (2006). Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain : a journal of neurology. open_in_new
Findings: Training improved exercise measures and quality-of-life scores; detraining reversed adaptations without measured mutation-load change.
Population: Eight adults with single large-scale mtDNA deletions
Limits: Small deletion-specific cohort; not direct m.3243A>G evidence and long-term safety remains uncertain.
Jeppesen TD. (2020). Aerobic Exercise Training in Patients With mtDNA-Related Mitochondrial Myopathy. Frontiers in physiology. open_in_new
Findings: Summarises potential improvements in oxidative capacity and exercise tolerance with training.
Population: Review of aerobic training in mtDNA-related myopathy
Limits: Small selected studies and limited long-term follow-up do not establish universal safety.
Jeppesen TD, Madsen KL, Poulsen NS, Løkken N, Vissing J. (2021). Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations. Journal of clinical medicine. open_in_new
Findings: Discusses physiological testing for diagnosis, functional assessment and treatment follow-up.
Population: Review of exercise testing in mtDNA-related myopathy
Limits: Tests and training effects depend on phenotype; no universal exertion target.
Wan Q, Ding Y, Liu W, Yang K. (2026). Effects of exercise training on skeletal muscle function in patients with mitochondrial myopathy: a systematic review. Frontiers in sports and active living. open_in_new
Findings: Fifteen small studies mostly reported improved exercise or muscle measures with training; only one was randomised and long-term evidence remains limited.
Population: 157 people with mitochondrial myopathy across 15 studies
Limits: Four to twenty participants per study, mostly non-randomised, heterogeneous genotypes and short follow-up.
Martin I, Flickinger J, Rahaman I, Sarna T, Ballance EB, Ginelli N, Peterson JT, Uryash A, Adams JA, Xiao R, Zolkipli-Cunningham Z. (2026). Quantitative assessment of efficacy and evaluation of feasibility of exercise training protocols in adult and pediatric primary mitochondrial disease. BMC medicine. open_in_new
Findings: Review and feasibility assessment identified exercise approaches meriting future rigorous trials.
Population: 77 exercise studies, 109 protocols across primary and secondary mitochondrial dysfunction
Limits: Mixed primary/secondary disease and heterogeneous protocols; feasibility rankings are not prescriptions or established safety for every patient.
Horne JT, Allen NE, Paul SS, Walker J, Sue C. (2026). MITO-VATION: Feasibility of a technology-supported structured home exercise program in Mitochondrial Disease. PLOS digital health. open_in_new
Findings: An eight-week technology-supported home programme was feasible for some participants but did not produce meaningful physical or fatigue improvements.
Population: 10 people with mild-to-moderate primary mitochondrial disease
Limits: Feasibility study with limited uptake and variable adherence; not an efficacy trial.
Tsai YL, Cheng KY, Lu YS, Lin KL. (2026). Cardiopulmonary Exercise Testing (CPET) Guided Sub-Anaerobic Threshold Rehabilitation in MELAS Syndrome: A Case Report. The Kaohsiung journal of medical sciences. open_in_new
Findings: Bibliographic record verified; no abstract available in the retrieved record. Full text must be assessed before using this source to support a claim.
Population: Not yet extracted
Limits: No findings assessed. Title alone is not evidence.
Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. (2003). The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain : a journal of neurology. open_in_new
Findings: Exercise physiology showed impaired oxygen extraction and broad variation in peak exercise capacity.
Population: 40 heterogeneous mitochondrial myopathy patients and sedentary controls
Limits: Physiological associations are not a validated exercise prescription or a deterministic genotype forecast.
Siciliano G, Simoncini C, Lo Gerfo A, Orsucci D, Ricci G, Mancuso M. (2012). Effects of aerobic training on exercise-related oxidative stress in mitochondrial myopathies. Neuromuscular disorders : NMD. open_in_new
Findings: Ten weeks of aerobic training reduced some circulating oxidative-stress measures.
Population: Seven adults with mitochondrial disease
Limits: Small study with surrogate outcomes; not proof of disease modification or universal safety.
Newell C, Ramage B, Robu I, Shearer J, Khan A. (2017). Side alternating vibration training in patients with mitochondrial disease: a pilot study. Archives of physiotherapy. open_in_new
Findings: A vibration-platform crossover pilot reported improved peak jump power during the treatment phase.
Population: 13 mitochondrial disease participants; seven adherent participants analysed
Limits: Small adherent-only analysis, attrition and limited outcomes; efficacy remains uncertain.
Voet NB, van der Kooi EL, van Engelen BG, Geurts AC. (2019). Strength training and aerobic exercise training for muscle disease. The Cochrane database of systematic reviews. open_in_new
Findings: Cochrane review found very low-certainty mitochondrial myopathy training evidence with imprecise functional effects.
Population: 14 exercise trials across muscle diseases; one mitochondrial myopathy group of 18
Limits: Most participants had other muscle diseases; do not pool their benefits as m.3243A>G evidence.
Klein IL, Verhaak CM, Smeitink JAM, de Laat P, Janssen MCH, Custers JAE. (2022). Identifying trajectories of fatigue in patients with primary mitochondrial disease due to the m.3243A > G variant. Journal of inherited metabolic disease. open_in_new
Findings: Fatigue trajectories differed over two years and were associated with disease manifestations and psychosocial burden.
Population: 53 adults with m.3243A>G
Limits: Observational cohort; does not establish a single cause of fatigue or a proven pacing intervention.
Clifford S, Stefanetti RJ, Bahar R, Hansson MJ, Gorman GS, Karaa A. (2025). Qualitative study of fatigue in adults with primary mitochondrial disease: Development of the PROMIS Fatigue Mitochondrial Disease Short Form. Molecular genetics and metabolism. open_in_new
Findings: Interviews informed a nine-item PMD-specific fatigue measure with initial content validity.
Population: 12 adults with genetically confirmed PMD and fatigue/myopathy
Limits: Selected qualitative sample; longitudinal psychometric properties and responsiveness require further testing.
Karaa A, Johnson N, Clarkson I, Newman W, Dorenbaum A, Cohen BH. (2024). Characterization of Fatigue in Primary Mitochondrial Myopathies: Findings From a Qualitative Interview Study. Neurology. Clinical practice. open_in_new
Findings: Qualitative interviews identified fatigue burden and supported relevance of the Modified Fatigue Impact Scale.
Population: 16 people aged at least 16 with primary mitochondrial myopathy
Limits: Content-validity study; not evidence that an intervention improves fatigue or that a score predicts progression.
Parikh S, Galioto R, Lapin B, Haas R, Hirano M, Koenig MK, Saneto RP, Zolkipli-Cunningham Z, Goldstein A, Karaa A. (2019). Fatigue in primary genetic mitochondrial disease: No rest for the weary. Neuromuscular disorders : NMD. open_in_new
Findings: Fatigue, mood symptoms and sleep problems were associated in questionnaire assessments.
Population: 48 adults with genetically confirmed primary mitochondrial disease
Limits: Measure-dependent prevalence and observational associations; no single causal explanation or proven pacing protocol.
DiVito D, Wellik A, Burfield J, Peterson J, Flickinger J, Tindall A, Albanowski K, Vishnubhatt S, MacMullen L, Martin I, Muraresku C, McCormick E, George-Sankoh I, McCormack S, Goldstein A, Ganetzky R, Yudkoff M, Xiao R, Falk MJ, R Mascarenhas M, Zolkipli-Cunningham Z. (2023). Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of Life. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. open_in_new
Findings: In a 60-person cohort, inadequate intake and malnutrition occurred, and nutrient intake correlated with some muscle and quality-of-life measures.
Population: 22 adults and 38 children with genetically confirmed primary mitochondrial disease; exclusively tube-fed people excluded
Limits: Observational correlations and estimated energy requirements; does not prove that a specific diet improves outcomes.
Batten K, Bhattacharya K, Simar D, Broderick C. (2023). Exercise testing and prescription in patients with inborn errors of muscle energy metabolism. Journal of inherited metabolic disease. open_in_new
Findings: Discusses benefits and limitations of exercise testing and individual prescription.
Population: Review of adults and children with muscle energy metabolism disorders
Limits: Includes McArdle and fatty-acid oxidation disorders as well as mitochondrial myopathy; paediatric evidence is limited.
de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. (2012). Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. Journal of inherited metabolic disease. open_in_new
Findings: Reports variable features and tissue/age-dependent heteroplasmy, supporting urinary epithelial testing.
Population: 34 Dutch families, 82 carriers among 127 participants
Limits: Related family members and selected cohort; contains a correction and cannot define individual severity.
Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF. (2017). Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: Uses expert Delphi consensus to organise routine care of primary mitochondrial disease.
Population: Mitochondrial Medicine Society care consensus
Limits: Abstract only here; detailed site recommendations use the assessed full-text Australian adaptation and newer topic guidance.
Pregnancy and family planning
22 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Kuikka P, Nikkinen H, Majamaa K, Martikainen MH. (2026). Obstetric history of women with m.3243A>G: an observational cohort study. Journal of medical genetics. open_in_new
Findings: A retrospective m.3243A>G cohort reported successful pregnancies alongside increased maternal complications; estimates differed from earlier cohorts.
Population: 16 women and 38 pregnancies
Limits: Small retrospective cohort spanning many decades, not a personal risk calculator.
Sanchez-Lechuga B, Salvucci M, Ng N, Kinsley B, Hatunic M, Kennelly M, Edwards J, Fleming A, Byrne B, Byrne MM. (2024). A retrospective cohort study evaluating pregnancy outcomes in women with MIDD. Acta diabetologica. open_in_new
Findings: Retrospective cohort reports miscarriage, gestational diabetes and other obstetric complications with variable outcomes.
Population: 88 pregnancies in 26 women, 25 with m.3243A>G
Limits: Small selected cohort; maternal-offspring correlation does not reliably predict severity and risks differ across cohorts.
Hui L, Hayman P, Buckland A, Fahey MC, Mackey DA, Mallett AJ, Schweitzer DR, Stuart CP, Yau WY, Christodoulou J. (2025). Pregnancy in women with mitochondrial disease-A literature review and suggested guidance for preconception and pregnancy care. The Australian & New Zealand journal of obstetrics & gynaecology. open_in_new
Findings: Pregnancy outcomes vary; a review recommends coordinated preconception, antenatal, delivery and postnatal care, including organ assessment and medication review.
Population: Five cohorts and 19 case reports covering mitochondrial disease pregnancies
Limits: Small heterogeneous, often retrospective reports; complication percentages are not individual predictions.
de Laat P, Fleuren LH, Bekker MN, Smeitink JA, Janssen MC. (2015). Obstetric complications in carriers of the m.3243A>G mutation, a retrospective cohort study on maternal and fetal outcome. Mitochondrion. open_in_new
Findings: Questionnaire study reports preterm delivery, pre-eclampsia and gestational diabetes.
Population: 60 responding women; 98 pregnancies in 46 m.3243A>G carriers
Limits: Retrospective self-report and national comparison; frequencies differ from other cohorts.
Karaa A, Elsharkawi I, Clapp MA, Balcells C. (2019). Effects of mitochondrial disease/dysfunction on pregnancy: A retrospective study. Mitochondrion. open_in_new
Findings: Reports symptom exacerbation and obstetric concerns alongside many term deliveries.
Population: Retrospective survey of 103 previously pregnant women with mitochondrial disease/dysfunction
Limits: Mixed diagnostic certainty and self-report; not a genotype-specific risk estimate.
Balachandran Nair D, Bloomfield M, Parasuraman R, Howe DT. (2021). Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome in pregnancy. BMJ case reports. open_in_new
Findings: Case report describes individual pregnancy management and relevant clinical concerns.
Population: One 39-year-old woman with MELAS in her eighth pregnancy
Limits: Single case; abstract does not establish general pregnancy risk or a standard regimen.
Lan X, Ao WL, Li J. (2024). Preimplantation genetic testing as a preventive strategy for the transmission of mitochondrial DNA disorders. Systems biology in reproductive medicine. open_in_new
Findings: Preimplantation genetic testing can inform embryo selection for mtDNA disease, with challenges in thresholds and residual risk.
Population: Review of PGT for mitochondrial DNA disorders
Limits: Embryo testing does not guarantee a disease-free child; counselling must be variant-specific.
Ji D, Zhang N, Zou W, Zhang Z, Marley JL, Liu Z, Liang C, Shen L, Liu Y, Liang D, Su T, Du Y, Cao Y. (2023). Modeling-based prediction tools for preimplantation genetic testing of mitochondrial DNA diseases: estimating symptomatic thresholds, risk, and chance of success. Journal of assisted reproduction and genetics. open_in_new
Findings: Models estimated thresholds for two variants but could not determine a symptomatic threshold for m.3243A>G.
Population: 455 individuals from 187 pedigrees in reproductive risk models
Limits: Model-based estimates and selected pedigrees; reproductive success and disease prediction remain uncertain.
Smeets HJM, Sallevelt SCEH, Herbert M. (2023). Reproductive options in mitochondrial disease. Handbook of clinical neurology. open_in_new
Findings: Heteroplasmic mtDNA transmission and phenotype prediction are complicated by the bottleneck. Genetic counselling discusses natural conception, prenatal testing, PGT, donation and other choices. Reproductive counselling considers maternal transmission, the mitochondrial bottleneck, prenatal and embryo testing, and donation approaches.
Population: Review of mitochondrial DNA inheritance and reproductive options
Limits: Availability and predictive value vary by variant, tissue, family and jurisdiction.
Castelluccio N, Spath K, Li D, De Coo IFM, Butterworth L, Wells D, Mertes H, Poulton J, Heindryckx B. (2025). Genetic and reproductive strategies to prevent mitochondrial diseases. Human reproduction update. open_in_new
Findings: Reproductive strategies can reduce transmission risk but have limitations and safety concerns requiring personalised counselling and follow-up.
Population: mtDNA reproductive strategies
Limits: Review; no universal guarantee of unaffected offspring or eligibility.
Spath K, Babariya D, Konstantinidis M, Lowndes J, Child T, Grifo JA, Poulton J, Wells D. (2021). Clinical application of sequencing-based methods for parallel preimplantation genetic testing for mitochondrial DNA disease and aneuploidy. Fertility and sterility. open_in_new
Findings: Combined PGT for mtDNA and aneuploidy was technically feasible, with variable embryo mutation findings.
Population: Four reproductive patients with three different mtDNA variants
Limits: Preclinical validation plus small cases; births reported for other variant families do not prove m.3243A>G success rates.
Sallevelt SCEH, Dreesen JCFM, Coonen E, Paulussen ADC, Hellebrekers DMEI, de Die-Smulders CEM, Smeets HJM, Lindsey P. (2017). Preimplantation genetic diagnosis for mitochondrial DNA mutations: analysis of one blastomere suffices. Journal of medical genetics. open_in_new
Findings: Re-analysis found low estimated false-negative risk for a specific single-blastomere PGT protocol.
Population: 294 blastomeres from 73 embryos in nine m.3243A>G carriers
Limits: Centre-specific threshold and embryo-stage data; authors’ extension to all variants requires caution.
Vachin P, Adda-Herzog E, Chalouhi G, Elie C, Rio M, Rondeau S, Gigarel N, Jabot Hanin F, Monnot S, Borghese R, Bengoa J, Ville Y, Rotig A, Munnich A, Bonnefont JP, Steffann J. (2018). Segregation of mitochondrial DNA mutations in the human placenta: implication for prenatal diagnosis of mtDNA disorders. Journal of medical genetics. open_in_new
Findings: Mutation load varied across placental samples, especially at intermediate levels, complicating CVS interpretation.
Population: 11 placentas carrying five different mtDNA variants
Limits: Small genotype-mixed tissue study; prenatal interpretation must be variant- and sample-specific.
Smeets HJ, Sallevelt SC, Dreesen JC, de Die-Smulders CE, de Coo IF. (2015). Preventing the transmission of mitochondrial DNA disorders using prenatal or preimplantation genetic diagnosis. Annals of the New York Academy of Sciences. open_in_new
Findings: Describes prenatal and embryo testing, donor eggs and experimental reproductive approaches.
Population: Review of reproductive testing in mtDNA disorders
Limits: Historical threshold and preferred-option claims require updated variant-specific counselling; no universal 18% guarantee.
Sallevelt SC, Dreesen JC, Drüsedau M, Spierts S, Coonen E, van Tienen FH, van Golde RJ, de Coo IF, Geraedts JP, de Die-Smulders CE, Smeets HJ. (2013). Preimplantation genetic diagnosis in mitochondrial DNA disorders: challenge and success. Journal of medical genetics. open_in_new
Findings: Reports embryo testing feasibility and within-embryo heteroplasmy variation; the reported birth followed m.8993T>G treatment.
Population: Nine PGT cycles in four carriers, three m.3243A>G and one m.8993T>G
Limits: Very small genotype-mixed experience; transfer thresholds are centre-specific and do not guarantee m.3243A>G outcomes.
Monnot S, Gigarel N, Samuels DC, Burlet P, Hesters L, Frydman N, Frydman R, Kerbrat V, Funalot B, Martinovic J, Benachi A, Feingold J, Munnich A, Bonnefont JP, Steffann J. (2011). Segregation of mtDNA throughout human embryofetal development: m.3243A>G as a model system. Human mutation. open_in_new
Findings: Examines m.3243A>G segregation during development and individual variation in bottleneck behaviour.
Population: Eight carrier women, 38 embryos and 12 fetuses
Limits: Small reproductive tissue study; does not guarantee prenatal prediction or embryo outcome.
Hellebrekers DM, Wolfe R, Hendrickx AT, de Coo IF, de Die CE, Geraedts JP, Chinnery PF, Smeets HJ. (2012). PGD and heteroplasmic mitochondrial DNA point mutations: a systematic review estimating the chance of healthy offspring. Human reproduction update. open_in_new
Findings: Models possible mutation-load thresholds for reproductive selection while recognising uncertainty and an m.3243A>G exception.
Population: Systematic review of 159 heteroplasmic variants and selected pedigrees
Limits: Estimation from muscle and pedigree data is not a universal safe embryo threshold; newer variant-specific counselling required.
Poulton J, Finsterer J, Yu-Wai-Man P. (2017). Genetic Counselling for Maternally Inherited Mitochondrial Disorders. Molecular diagnosis & therapy. open_in_new
Findings: Discusses recurrence uncertainty, heteroplasmy and multidisciplinary reproductive counselling.
Population: Review of maternally inherited mitochondrial disorders
Limits: Variant-specific inheritance differs; general recurrence numbers are not m.3243A>G personal risks.
Zhang J, Liu H, Luo S, Lu Z, Chávez-Badiola A, Liu Z, Yang M, Merhi Z, Silber SJ, Munné S, Konstantinidis M, Wells D, Tang JJ, Huang T. (2017). Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reproductive biomedicine online. open_in_new
Findings: Reports a live birth with low but detectable mutation levels and early follow-up.
Population: One donor-spindle-transfer birth for m.8993T>G risk
Limits: Different variant, single birth and seven-month observation; no proof of lifelong safety or zero transmission.
Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, Knowles CVY, Patel Y, Hodsdon P, Baines JP, Blakely EL, Polke J, Taylor RW, Fratter C. (2023). Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. European journal of human genetics : EJHG. open_in_new
Findings: m.3243A>G may decline in blood with age; urine can improve detection. Assay sensitivity and clinical suspicion guide sample selection. Muscle biopsy is no longer routine first-line testing.
Population: People investigated for mitochondrial disease
Limits: Guideline; laboratory methods, age and clinical phenotype affect sensitivity.
Zhou MC, Min R, Ji JJ, Zhang S, Tong AL, Xu JP, Li ZY, Zhang HB, Li YX. (2015). Analysis of association among clinical features and shorter leukocyte telomere length in mitochondrial diabetes with m.3243A>G mitochondrial DNA mutation. BMC medical genetics. open_in_new
Findings: Two of five female probands had oligomenorrhea with low FSH/LH; authors interpreted this as hypogonadotropic hypogonadism.
Population: 15 m.3243A>G diabetes patients from five Chinese families; five female probands
Limits: Small selected family study; did not measure time to pregnancy or infertility incidence and cannot establish the variant as the cause of an individual fertility problem.
Gorman GS, Grady JP, Turnbull DM. (2015). Mitochondrial donation--how many women could benefit? The New England journal of medicine. open_in_new
Findings: A UK cohort of 154 women carrying inherited mtDNA variants had no statistically significant difference in live-birth rates from the general population (63.2 vs 67.2 per 1000; P=0.36).
Population: 154 women with inherited mtDNA variants in the UK MRC mitochondrial disease cohort
Limits: Mixed variants; live-birth rates are not time-to-pregnancy measurements. Non-significance does not establish equivalence or exclude individual fertility difficulties. Only the relevant publisher excerpt was assessed.
Children, daily life and support
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Schofield D, Kraindler J, Lim K, Tan O, Haque S, Crawley K, West S, Percival A, Parmar J, Shrestha R, Sue C. (2025). Health-related quality of life in patients with mitochondrial disease and their carers. Journal of medical genetics. open_in_new
Findings: Health utility scores were below population norms for patients and carers, with associations involving mood, sleep and financial strain.
Population: 99 adult mitochondrial patients and 24 carers in Australian EPIC-MITO study
Limits: Selected regional cohort and observational modelling; not universal values or intervention effects.
Verhaak C, de Laat P, Koene S, Tibosch M, Rodenburg R, de Groot I, Knoop H, Janssen M, Smeitink J. (2016). Quality of life, fatigue and mental health in patients with the m.3243A > G mutation and its correlates with genetic characteristics and disease manifestation. Orphanet journal of rare diseases. open_in_new
Findings: Fatigue and mental health symptoms can affect quality of life in m.3243A>G disease; mutation load alone is not an adequate explanation.
Population: 72 adult m.3243A>G carriers
Limits: Questionnaire measures are not equivalent to a clinical psychiatric diagnosis; cross-sectional associations.
Rosella LC, Hurst M, Buajitti E, Samson T, Young LT, Andreazza AC. (2025). A population-based cohort study of mitochondrial disease and mental health conditions in Ontario, Canada. Orphanet journal of rare diseases. open_in_new
Findings: Administrative cohort links recorded mental-health conditions with greater healthcare use and cost in mitochondrial disease.
Population: Ontario linked population health databases with MS comparator
Limits: Coding, ascertainment and health-system context limit interpretation; associations are not causal.
Zhao X, Yu M, Zhang W, Hou Y, Yuan Y, Wang Z. (2024). Demographic characteristics, diagnostic challenges, treatment patterns, and caregiver burden of mitochondrial diseases: a retrospective cross-sectional study. Orphanet journal of rare diseases. open_in_new
Findings: Survey describes diagnostic difficulty, treatment use and caregiver/economic burden.
Population: 183 patients at one Chinese hospital, including 124 children
Limits: Single-centre retrospective sample; costs are context-specific and supplement use is not efficacy evidence.
Heath O, Hammerl E, Spitzinger A, Wortmann SB. (2024). Ending an Odyssey? The Psychosocial Experiences of Parents after the Genetic Diagnosis of a Mitochondrial Disease in Children. Journal of personalized medicine. open_in_new
Findings: Parents described diagnostic value alongside continuing uncertainty, relationship strain and unmet support needs.
Population: 24 interviews with parents of 13 children with primary mitochondrial disease
Limits: Qualitative selected families; preferences for support differed and are not universal.
van de Loo KFE, Custers JAE, de Boer L, van Lieshout M, de Vries MC, Janssen MCH, Verhaak CM. (2022). Cognitive functioning and mental health in children with a primary mitochondrial disease. Orphanet journal of rare diseases. open_in_new
Findings: Cognitive ability ranged widely; specific attention, processing and mental-health difficulties occurred across ability levels.
Population: 33 children with genetically confirmed mitochondrial disease
Limits: Small cohort with differing denominators and assessments; not all children share the same needs.
van de Loo KFE, van Zeijl NT, Custers JAE, Janssen MCH, Verhaak CM. (2022). A conceptual disease model for quality of life in mitochondrial disease. Orphanet journal of rare diseases. open_in_new
Findings: A conceptual model linked fatigue and physical function to quality of life and participation.
Population: 95 genetically confirmed mitochondrial disease patients
Limits: Observational modelling does not establish causality or efficacy of a particular support intervention.
Klein IL, Verhaak CM, Smeitink JAM, de Laat P, Janssen MCH, Custers JAE. (2022). Identifying trajectories of fatigue in patients with primary mitochondrial disease due to the m.3243A > G variant. Journal of inherited metabolic disease. open_in_new
Findings: Fatigue trajectories differed over two years and were associated with disease manifestations and psychosocial burden.
Population: 53 adults with m.3243A>G
Limits: Observational cohort; does not establish a single cause of fatigue or a proven pacing intervention.
Clifford S, Stefanetti RJ, Bahar R, Hansson MJ, Gorman GS, Karaa A. (2025). Qualitative study of fatigue in adults with primary mitochondrial disease: Development of the PROMIS Fatigue Mitochondrial Disease Short Form. Molecular genetics and metabolism. open_in_new
Findings: Interviews informed a nine-item PMD-specific fatigue measure with initial content validity.
Population: 12 adults with genetically confirmed PMD and fatigue/myopathy
Limits: Selected qualitative sample; longitudinal psychometric properties and responsiveness require further testing.
Winqvist S, Kärppä M, Moilanen JS, Majamaa K. (2025). Cognitive impairment profile in patients with the m.3243A> G variant in mitochondrial DNA. BMC neurology. open_in_new
Findings: Neuropsychological assessment found variable impairment across domains, associated with phenotype burden and heteroplasmy.
Population: 45 adult m.3243A>G patients and 45 healthy controls
Limits: Selected observational cohort; does not establish inevitable major impairment or future decline.
Moore HL, Kelly T, Bright A, Field RH, Schaefer AM, Blain AP, Taylor RW, McFarland R, Turnbull DM, Gorman GS. (2019). Cognitive deficits in adult m.3243A>G- and m.8344A>G-related mitochondrial disease: importance of correcting for baseline intellectual ability. Annals of clinical and translational neurology. open_in_new
Findings: Repeated cognitive testing showed that baseline intellectual ability and disease severity affected interpretation of deficits.
Population: 49 adults, 36 m.3243A>G and 13 m.8344A>G, with 32 matched controls
Limits: Selected mixed cohort and 18-month follow-up; does not imply rapid cognitive decline for every carrier.
Primiano G, Brunetti V, Vollono C, Losurdo A, Moroni R, Della Marca G, Servidei S. (2021). Sleep-Disordered Breathing in Adult Patients With Mitochondrial Diseases: A Cohort Study. Neurology. open_in_new
Findings: Sleep-disordered breathing was frequent, with patterns differing across phenotype/genotype groups.
Population: 103 adults with genetically confirmed mitochondrial disease undergoing polysomnography
Limits: Selected mixed cohort; subgroup percentages should not be applied to all m.3243A>G carriers.
Brunetti V, Della Marca G, Servidei S, Primiano G. (2021). Sleep Disorders in Mitochondrial Diseases. Current neurology and neuroscience reports. open_in_new
Findings: Describes sleep-disordered breathing and phenotype-related differences.
Population: Review of sleep disorders in mitochondrial disease
Limits: Broad screening recommendation is expert interpretation; individual assessment and newer guidance remain important.
Riquin E, Le Nerzé T, Pasquini N, Barth M, Prouteau C, Colin E, Amati Bonneau P, Procaccio V, Van Bogaert P, Duverger P, Bonneau D, Roy A. (2021). Psychiatric Symptoms of Children and Adolescents With Mitochondrial Disorders: A Descriptive Case Series. Frontiers in psychiatry. open_in_new
Findings: Prospective descriptive series reports mood, anxiety and quality-of-life concerns.
Population: 12 children and adolescents with mitochondrial disorders
Limits: Small mixed cohort and different instruments; not a general paediatric prevalence estimate.
Fattal O, Link J, Quinn K, Cohen BH, Franco K. (2007). Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS spectrums. open_in_new
Findings: Psychiatric diagnoses were frequent and associated with lower reported quality of life in this cohort.
Population: 36 adults with mitochondrial cytopathies interviewed
Limits: Small mixed cohort; prevalence and associations do not establish causation or all-carrier risk.
Bertini E, Gregg E, Bartlett C, Senthilnathan V, Arber M, Watkins D, Graziadio S, Tomazos I. (2023). The burden of mitochondrial disease with associated seizures: systematic literature reviews of health-related quality of life, utilities, costs and healthcare resource use data. Orphanet journal of rare diseases. open_in_new
Findings: Limited studies showed impaired patient/caregiver quality of life and parenting stress; costs and resource evidence was sparse.
Population: Systematic reviews of mitochondrial disease with seizures
Limits: Different instruments and very few resource studies; no robust cost or admission-duration estimate.
Medrano P, Banderas B, Brimmer M, Settel L, Berger S, Shields A, Goldstein A, Karaa A, Larson A, Parikh S, Scaglia F, Harrington KD, Edgar CJ, Ventola P, Webster M, Chickering J, Gwaltney C, Wilson P, Glasser C. (2025). Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectives. Journal of patient-reported outcomes. open_in_new
Findings: Interviews identified fatigue, hearing loss, cognitive symptoms and work/emotional impacts as important patient-centred outcomes.
Population: 16 adults with MELAS and five experts interviewed
Limits: Qualitative sample; frequencies are interview counts, not population prevalence.
Dumbuya JS, Tian C, Deng L, Ahmad B, Chen X, Lu J. (2025). Clinical features, disease burden and impact on quality of life in participants with mitochondrial encephalomyopathy. Frontiers in neurology. open_in_new
Findings: Cross-sectional measures linked quality of life, financial strain and caregiver burden.
Population: 27 mitochondrial encephalomyopathy participants, mostly children, and caregivers
Limits: Single-centre small heterogeneous sample; cannot infer universal cost burden or causation.
Uusimaa J, Moilanen JS, Vainionpää L, Tapanainen P, Lindholm P, Nuutinen M, Löppönen T, Mäki-Torkko E, Rantala H, Majamaa K. (2007). Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Annals of neurology. open_in_new
Findings: A population study found variable childhood features and transmission patterns, including learning and exercise difficulties.
Population: Defined Finnish paediatric population; 18 identified children plus family analyses
Limits: Geographically specific ascertainment and small family sample; transmission rates are not individual predictions.
Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF. (2017). Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in medicine : official journal of the American College of Medical Genetics. open_in_new
Findings: Uses expert Delphi consensus to organise routine care of primary mitochondrial disease.
Population: Mitochondrial Medicine Society care consensus
Limits: Abstract only here; detailed site recommendations use the assessed full-text Australian adaptation and newer topic guidance.
Emerging treatments and trials
20 selected papers. Entries may appear in more than one collection. Selection does not imply that a treatment works or that every paper has been fully assessed.
Smeitink J, van Es J, Bosman B, Janssen MCH, Klopstock T, Gorman G, Vissing J, Ruiterkamp G, Edgar CJ, Abbink EJ, van Maanen R, Pogoryelova O, Stendel C, Bischoff A, Karin I, Munshi M, Kümmel A, Burgert L, Verhaak C, Renkema H. (2025). Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain : a journal of neurology. open_in_new
Findings: The 27-person phase 2b study did not meet its primary cognitive endpoint. Secondary/subgroup and open-label extension signals require confirmation.
Population: 27 adults with m.3243A>G; 12 in extension analysis
Limits: Small study, multiple exploratory outcomes, selected baseline analyses and uncontrolled extension limit efficacy inference.
Pizzamiglio C, Stefanetti RJ, McFarland R, Thomas N, Ransley G, Hugerth M, Grönberg A, Serrano SS, Elmér E, Hanna MG, Hansson MJ, Gorman GS, Pitceathly RDS. (2025). Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease. Brain : a journal of neurology. open_in_new
Findings: KL1333 study reports tolerability, dose-related GI effects and exploratory fatigue/function signals that informed later trials.
Population: Healthy volunteers and adults with mitochondrial disease in phase 1a/1b study
Limits: Early-phase exploratory efficacy; abstract does not establish confirmatory benefit.
van Tienen FHJ, Hoeijmakers JGJ, van der Leij C, Timmer E, Wanders N, Lindsey PJ, Yi F, Lin F, Kortekaas SPM, Roelofs H, Westra IM, Meij P, Wijnen LACM, de Coo IFM, Smeets HJM. (2025). Intra-arterial transplantation of autologous mesoangioblasts in m.3243A>G mutation carriers is safe: First phase 1/2 human clinical study. Molecular therapy : the journal of the American Society of Gene Therapy. open_in_new
Findings: Local infusion caused transient discomfort without serious events in short follow-up; biopsies suggested early regeneration and culture increased mutation load.
Population: Three m.3243A>G carriers receiving autologous mesoangioblasts into one leg
Limits: Tiny first-in-human study, local intervention and four-week biopsy follow-up; no established lasting efficacy or general safety.
Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, Goldstein A, Gorman GS, Haas R, Hirano M, Klopstock T, Koenig MK, Kornblum C, Lamperti C, Lehman A, Longo N, Molnar MJ, Parikh S, Phan H, Pitceathly RDS, Saneto R, Scaglia F, Servidei S, Tarnopolsky M, Toscano A, Van Hove JLK, Vissing J, Vockley J, Finman JS, Brown DA, Shiffer JA, Mancuso M, MMPOWER-3 Trial Investigators. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. open_in_new
Findings: Twenty-four weeks of elamipretide did not improve either primary walking or fatigue endpoint versus placebo.
Population: 218 adults randomised in MMPOWER-3
Limits: Mixed mtDNA/nuclear myopathy population; subgroup or earlier exploratory findings cannot overturn the primary result.
Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. open_in_new
Findings: Five-day elamipretide trial showed exploratory dose-related walking signals; highest-dose unadjusted comparison was not statistically significant.
Population: 36 adults with primary mitochondrial myopathy in phase I/II MMPOWER
Limits: Short exposure and small sample; later MMPOWER-3 did not meet primary endpoints.
Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS, Hong X, Gooch CL, Mao X, Pascual JM, Hirano M, Stacpoole PW, DiMauro S, De Vivo DC. (2006). Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. open_in_new
Findings: A randomised MELAS trial was stopped early because DCA caused onset or worsening of peripheral neuropathy, with no demonstrated clinical benefit.
Population: 30 people aged 10–60 with m.3243A>G-associated MELAS
Limits: Studied regimen and population; do not generalise to every investigational metabolic indication.
Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y, KN01 Study Group. (2019). Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of neurology, neurosurgery, and psychiatry. open_in_new
Findings: Ten people received high-dose taurine in a 52-week open-label trial; fewer episodes were reported, but no placebo comparison establishes causality.
Population: 10 people with MELAS and recurrent stroke-like episodes
Limits: Uncontrolled small study, wide confidence intervals; not proof of prevention or general m.3243A>G benefit.
Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. (2018). Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. Journal of neurology. open_in_new
Findings: Small prospective Japanese oral and IV studies reported symptom and episode-related signals with arginine.
Population: 15 oral-treatment and 10 IV-treatment participants
Limits: No randomised comparator; small cohorts; natural variation and other treatments complicate attribution.
Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J. (2025). Therapies for Mitochondrial Disease: Past, Present, and Future. Journal of inherited metabolic disease. open_in_new
Findings: Small molecules, transplantation and genetic approaches are under investigation; translation is limited by delivery, disease heterogeneity, endpoints and scarce natural-history data.
Population: Broad mitochondrial disease treatment landscape
Limits: Review; developmental status and applicability need intervention-specific checking.
Stefanetti RJ, Charman SJ, Newman J, Hallsworth K, Blain AP, Ng YS, Gorman GS. (2025). Outcomes misaligned in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): implications for trial design. Brain communications. open_in_new
Findings: Objective disease burden and exercise measures diverged from patient-reported measures in the MELAS subgroup; trial endpoints need multiple perspectives.
Population: 16 analysed m.3243A>G carriers (6 MELAS, 10 non-MELAS)
Limits: Small cross-sectional study; no proof that individual symptom reports are unreliable.
Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. (2020). A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. open_in_new
Findings: Mitochondrial base editing enabled targeted DNA changes in human cells without a guide RNA. It differs from destroying mutant genomes with nucleases.
Population: Human cell models
Limits: Laboratory platform; not a tested treatment for people with m.3243A>G.
Yang Y, Wu H, Kang X, Liang Y, Lan T, Li T, Tan T, Peng J, Zhang Q, An G, Liu Y, Yu Q, Ma Z, Lian Y, Soh BS, Chen Q, Liu P, Chen Y, Sun X, Li R, Zhen X, Liu P, Yu Y, Li X, Fan Y. (2018). Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. Protein & cell. open_in_new
Findings: Targeted mitoTALEN cleavage reduced mutant load and restored selected cellular bioenergetic measures.
Population: Patient-derived m.3243A>G iPSCs and experimental porcine oocytes
Limits: Preclinical cells and oocytes; lack of detected off-target change in tested clones does not establish human safety.
Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT. (2015). MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases. Molecular therapy : the journal of the American Society of Gene Therapy. open_in_new
Findings: MitoTALENs reduced targeted mutant mtDNA and improved respiratory measures in cell lines.
Population: Cybrid cells carrying m.8344A>G or m.13513G>A
Limits: Other-variant cell evidence; delivery and safety in m.3243A>G patients are unproven.
Silva-Pinheiro P, Nash PA, Van Haute L, Mutti CD, Turner K, Minczuk M. (2022). In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue. Nature communications. open_in_new
Findings: AAV-delivered DdCBE installed mtDNA edits in vivo as proof of concept.
Population: Adult and neonatal mouse heart tissue
Limits: Animal mutagenesis study; not m.3243A>G correction or demonstrated patient benefit.
Joore IP, Shehata S, Muffels I, Castro-Alpízar J, Jiménez-Curiel E, Nagyova E, Levy N, Tang Z, Smit K, Vermeij WP, Rodenburg R, Schiffelers R, Nieuwenhuis EES, van Hasselt PM, Fuchs SA, Koppens MAJ. (2025). Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoS biology. open_in_new
Findings: Base editing corrected a different pathogenic mtDNA variant in patient-derived fibroblasts and created disease models in organoids.
Population: m.4291T>C fibroblasts and m.15150G>A organoids
Limits: Cell/organoid experiments with different variants; clinical delivery and safety remain unresolved.
Barrera-Paez JD, Bacman SR, Balla T, Van Booven D, Gannamedi DP, Stewart JB, Mok B, Liu DR, Lombard DB, Griswold AJ, Nedialkova DD, Moraes CT. (2025). Correcting a pathogenic mitochondrial DNA mutation by base editing in mice. Science translational medicine. open_in_new
Findings: A compensatory mtDNA edit improved molecular measures in a mouse model, while the highest vector dose caused severe adverse effects and off-target editing.
Population: Mouse mt-tRNA-Ala model, not m.3243A>G
Limits: Preclinical and variant-specific; evidence of safety challenges rather than an available cure.
Burg L, Yoon H, Peng M, Germano P, Reesey Gretzmacher E, Xiao R, Anderson VE, Nakamaru-Ogiso E, Falk MJ. (2025). Zagociguat prevented stressor-induced neuromuscular dysfunction, improved mitochondrial physiology, and increased exercise capacity in diverse mitochondrial respiratory chain disease zebrafish models. Frontiers in pharmacology. open_in_new
Findings: Zagociguat improved selected physiological or movement outcomes in some models but not all.
Population: Multiple genetic and toxin-induced zebrafish respiratory-chain models
Limits: Preclinical model-dependent findings; no proof of MELAS patient efficacy or current trial status.
Marchet S, Catania A, Ardissone A, Montano V, Einvag K, Iermito MP, Sala D, Spagnolo M, Mauro E, Lamantea E, Cecchi G, Lopriore P, Mancuso M, Lamperti C. (2025). PHEMI-Phenylbutyrate in Patients With Lactic Acidosis: A Pilot, Single Arm, Phase I/II, Open-Label Trial. Clinical therapeutics. open_in_new
Findings: Phenylbutyrate pilot encountered adverse effects in adults at the initial dose; the lower dose did not meet the primary outcome.
Population: Nine participants: three children with PDH deficiency and six adults with MELAS
Limits: Open single-arm mixed-disease study; cellular lactate changes do not establish clinical benefit.
Smeitink J, van Maanen R, de Boer L, Ruiterkamp G, Renkema H. (2022). A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC"). BMC neurology. open_in_new
Findings: KHENERGYC protocol describes pharmacokinetic and placebo-controlled sonlicromanol assessment.
Population: Planned 24 children with genetically confirmed mitochondrial disease
Limits: Protocol without efficacy results; historical recruitment language is not current status.
Stefanetti RJ, Pizzamiglio C, Blain AP, Russell OM, Alcock L, Hudson G, Newman J, Thomas N, Warren C, Su H, Tuppen HAL, Brown P, Houghton D, Hunter H, Lim AZ, Ng YS, Feeney C, Skorupinska I, Germain L, Bugiardini E, Hanna MG, McFarland R, Pitceathly RDS, Gorman GS. (2026). Mavodelpar in patients with primary mitochondrial myopathy: a phase 1 trial. Scientific reports. open_in_new
Findings: Open-label mavodelpar phase 1b study reported mostly mild/moderate adverse events and exploratory functional changes; authors state subsequent phase 2b did not show efficacy.
Population: 23 adults with primary mitochondrial myopathy
Limits: Only 17 completed initial phase; no comparator, early termination, exploratory outcomes are not demonstrated benefit.
Related patient guides
Use the topic links below to continue reading at your preferred level of detail.
m.3243A>G foundations expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
MIDD expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
MELAS expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Symptoms and organ involvement expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Diagnosis and monitoring expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Care and emergencies expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Medication safety expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Supplements and adjunctive treatments expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Nutrition expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Exercise, fatigue and rehabilitation expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Pregnancy and family planning expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Children, daily life and support expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
Emerging treatments and trials expand_more
Continue to the related patient guides. Each guide lists the evidence used for its explanations.
You do not need to become a researcher to understand your condition.
Start with the question that matters to you. A source list makes the evidence easier to check; it cannot replace advice from a team who knows your health.